



(51) International Patent Classification:

G01N 33/68 (2006.01) C07K 7/06 (2006.01)
G01N 33/53 (2006.01) C07K 16/18 (2006.01)
C07K 7/08 (2006.01)

(21) International Application Number:

PCT/NZ2014/000234

(22) International Filing Date:

14 November 2014 (14.11.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/904,957 15 November 2013 (15.11.2013) US

(72) Inventors; and

(71) Applicants : LEE, Jacqueline Amanda [NZ/NZ]; 94 Crofton Road, Christchurch 8051 (NZ). PEMBERTON, Christopher Joseph [NZ/NZ]; 54 Steadman Road, Broomfield, Christchurch 8042 (NZ).

(74) Agent: CATALYST INTELLECTUAL PROPERTY; Level 5, 111 Customhouse Quay, Wellington 6011 (NZ).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: BIOMARKER FOR CARDIAC DISORDERS

FIGURE 1



(57) Abstract: The present invention relates generally to assays, methods and kits for the prognosis and/or diagnosis of cardiac disorders. The present invention also provides, for example, binding agents to a novel class of circulating cardiac troponin T upstream open reading frame (TnTuORF) peptide biomarkers for use in predicting or diagnosing a cardiac disorder other than myocardial infarction or unstable angina. In addition, the binding agents of the present invention may be used to enhance the sensitivity and false positive performance of cardiac troponins in the prognosis and diagnosis of myocardial infarction.

BIOMARKER FOR CARDIAC DISORDERS**TECHNICAL FIELD**

The present invention relates generally to methods, assays and kits for the prognosis
5 and/or diagnosis of cardiac disorders.

BACKGROUND OF THE INVENTION

The following includes information that may be useful in understanding the present
invention. It is not an admission that any of the information, publications or documents
10 specifically or implicitly referred to or referenced herein is prior art, or essential, to the
presently described or claimed inventions. All publications and patents mentioned in this
specification are incorporated herein by reference in their entirety.

The advent of highly sensitive (hs) assays for the detection of cardiac troponins
(cTn) has significantly altered our understanding of troponin in the circulation and altered
15 aspects of its use for the diagnosis of acute myocardial infarction (MI; Thygesen *et al.*
(2012) *Circulation* 126:2020-2035; Keller *et al.* (2009) *N. Eng. J. Med.* 361:868-877;
Reichlin *et al.* (2009) *N. Eng. J. Med.* 361:858-867). These assays have resulted in major
improvements in time to diagnosis of myocardial infarction (MI), but this has come at the
cost of increasing numbers of patients who have elevated levels of troponin above 99th
20 percentile guidelines, but do not in fact have MI (Reichlin *et al.* (2012) *Am. J. Med.*
125:1205-1213; Thygesen *et al.* (2012) *Eur. Heart J.* 33:2252-2257; Hammerer-Lercher *et al.*
(2013) *J. Am. Heart Assoc.* 2(3):e000204.doi:10.1161/JAHA.113.000204). This imbues
significant reductions in assay specificity and as a consequence several biomarker based
strategies have been suggested to help hscTn measurement (Eggers *et al.* (2008) *Eur.*
25 *Heart J.* 29:2327-2335; Haaf *et al.* (2011) *Am. J. Med.* 124:731-739; Maisel *et al.* (2013) *J.*
Am. Coll. Cardiol. 62:150-160; Cullen *et al.* (2013) *J. Am. Coll. Cardiol.* 62:1242-1249).
One potential strategy to overcome these limitations is consideration of total potential
cardiac troponin produced, including upstream open reading frame peptides.

Upstream open reading frames (uORFs) are amino acid coding sequences defined by
30 a start and stop codons upstream (5') of the main coding region in proteins. Approximately
40-50% of the human and mouse transcriptome contain uORFs (Calvo *et al.* (2009) *Proc.*
Natl. Acad. Sci. 106:7507-7512; Iacono *et al.* (2005) *Gene* 349:97-105) and they are less
frequent than expected by chance (Neafsey *et al.* (2007) *Mol. Biol. Evol.* 24:1744-1751)
suggesting they are under selective pressure. However, uORFs are overrepresented in the
35 protein subgroup containing transcription factors, growth factors, proto-oncogenes and their
receptors (Davuluri *et al.* (2000) *Genome Res.* 10:1807-1816). Adding to their complexity,
uORFs are extremely diverse varying in position in relation to the cap and main ORF AUG,
number per transcript and length (Calvo *et al.* (2009) *Proc. Natl. Acad. Sci.* 106:7507-7512;
Somers *et al.* (2013) *Int. J. Biochem. Cell Biol.* 45:1690-1700). In mammalian cells there is

limited experimental evidence concerning direct translational actions of uORFs upon cellular function and there is no evidence that uORF-derived peptides are present in the circulation. A single report has documented that the glucocorticoid receptor transcript 1A (GR-1A) possesses 5 uORF start sites in its 1026bp 5'-UTR. One of these uORFs encodes a 93 amino acid peptide that was detected in the nucleus, cytosol and plasma membrane of mouse and human cell cultures and was found to play a role in promoting GR-1A translation (Diba *et al.* (2001) *J. Cell. Biochem.* 81:149-161).

The Applicants demonstrate here that uORF peptides are present in the 5'-UTR of the human cardiac troponin T (TnT) gene and surprisingly provide the first direct evidence to demonstrate that a cardiac TnTuORF peptide is indeed present in the human circulation and that its assay quantitation has utility in the prognosis and diagnosis of cardiac disorders, and in improving the sensitivity and false positive performance of established biomarkers for cardiac disease, including myocardial infarction.

SUMMARY OF THE INVENTION

The inventions described and claimed herein have many attributes and embodiments including, but not limited to, those set forth or described or referenced in this Summary of the Invention. It is not intended to be all-inclusive and the inventions described and claimed herein are not limited to or by the features or embodiments identified in this Summary of the Invention, which is included for purposes of illustration only and not restriction.

The present invention relates generally to assays, methods and kits for the prognosis and/or diagnosis of cardiac disorders. In particular, the present invention relates to the use of a novel class of circulating biomarker encoded for by an upstream open reading frame of Troponin T and binding agents specific to this peptide in assays, methods and kits for the prognosis and/or diagnosis of, for example, cardiac disorders other than myocardial infarction or unstable angina.

In one aspect of the present invention there is provided a method of predicting a subject's risk of acquiring a cardiac disorder other than myocardial infarction or unstable angina, the method comprising:

- (i) measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from the subject; and
- (ii) comparing the measured level of the TnTuORF peptide against a reference interval from a suitable control population,

wherein an increase in the circulating level of the TnTuORF peptide compared with the control population is predictive of acquiring a cardiac disorder other than myocardial infarction or unstable angina, and further wherein the measuring step comprises detecting binding between the TnTuORF peptide and a binding agent that selectively binds to the TnTuORF peptide.

In one embodiment, the method further comprises the step of (iii) administering a treatment regime to the subject where the subject is found to have an increase in the circulating level of the TnTuORF peptide compared with the level of the circulating TnTuORF peptide from the control population.

5 In another embodiment, the method further comprises measuring the level of the TnTuORF peptide in a first biological sample from the subject and measuring the level of the TnTuORF peptide in a second biological sample, wherein the second biological sample is taken from the same subject as the first biological sample but at a later period in time, and comparing the levels of TnTuORF peptide in the first and second samples, wherein an
10 increase in the circulating level of TnTuORF peptide between the first and second samples is indicative of increased risk to acquiring a cardiac disorder other than myocardial infarction or unstable angina.

In another aspect of the present invention there is provided a method of diagnosing a cardiac disorder other than myocardial infarction or unstable angina in a subject, the
15 method comprising:

- (i) measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from the subject; and
- (ii) comparing the measured level of the TnTuORF peptide against a reference interval from a suitable control population,

20 wherein an increase in the circulating level of the TnTuORF peptide compared with the control population is indicative of a cardiac disorder other than myocardial infarction or unstable angina, and further wherein the measuring step comprises detecting binding between the TnTuORF peptide and a binding agent that selectively binds to the TnTuORF peptide.

25 In one embodiment, the method further comprises the step of (iii) administering a treatment regime to the subject where the subject is found to have an increase in the circulating level of the TnTuORF peptide compared with the level of the circulating TnTuORF peptide from the control population.

In another embodiment according to any aspect of the present invention, measuring
30 TnTuORF peptide in a biological sample may occur more than once. For example, one, two, three, four, five, ten, fifteen etc measurements may be performed over a period of time spanning hours, days, weeks, months or years.

In a further embodiment, the method comprises measuring the level of the TnTuORF peptide in a first biological sample from the subject and measuring the level of the TnTuORF
35 peptide in a second biological sample, wherein the second biological sample is taken from the same subject as the first biological sample but at a later period in time, and comparing the levels of the TnTuORF peptide in the first and second samples, wherein an increase in the circulating level of the TnTuORF peptide between the first and second samples is

indicative of a cardiac disorder other than myocardial infarction or unstable angina and/or persistence of a cardiac disorder other than myocardial infarction or unstable angina.

In certain embodiments according to any aspect of the present invention, the cardiac disorder other than myocardial infarction or unstable angina includes, for example, atrial
5 fibrillation, heart failure, pericarditis, vasovagalsyncope, disorders of nerve conduction and combinations thereof.

In yet another aspect of the present invention there is provided a method for monitoring the responsiveness of a subject to treatment with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina, the method comprising:

- 10 (i) measuring the level of a TnTuORF peptide in a first biological sample from the subject;
- (ii) measuring the level of a TnTuORF peptide in a second biological sample from the subject, wherein the second biological sample is taken from the same subject; and
- 15 (iii) comparing the measured levels of the TnTuORF peptide in the first and second samples,

wherein an increase in the level of TnTuORF peptide between the first and second samples is indicative of a poor response to treatment with a with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina and wherein a decrease
20 in the level of TnTuORF peptide between the first and second samples is indicative of a positive response to a to treatment with a with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina.

Contingent on the cardiac disorder to be treated, it is possible that an increased level of TnTuORF peptide between the first and second samples is indicative of a positive
25 response to treatment with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina. Put another way, a decreased level of TnTuORF peptide between the first and second samples is indicative of a poor response to treatment with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina.

Accordingly, in yet a further aspect of the present invention there is provided a
30 method for monitoring the responsiveness of a subject to treatment with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina, the method comprising:

- (i) measuring the level of a TnTuORF peptide in a first biological sample from the subject;
- 35 (ii) measuring the level of a TnTuORF peptide in a second biological sample from the subject, wherein the second biological sample is taken from the same subject; and
- (iii) comparing the measured levels of the TnTuORF peptide in the first and second samples,

wherein an decrease in the level of TnTuORF peptide between the first and second samples is indicative of a poor response to treatment with a with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina and wherein an increase in the level of TnTuORF peptide between the first and second samples is indicative of a positive response to a to treatment with a with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina.

In other embodiments according to any method disclosed herein, the measuring step comprises detecting binding between a TnTuORF peptide and a binding agent that selectively binds to the TnTuORF peptide. In one embodiment, the binding agent is an antibody or antigen-binding fragment thereof. In another embodiment, the antibody is a monoclonal antibody or antigen-binding fragment thereof. In other embodiments, binding to the TnTuORF peptide is measured using antibodies that are immobilised to a solid phase.

In a further aspect of the present invention there is provided an assay for measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from a subject with, or at risk of acquiring, a cardiac disorder other than myocardial infarction or unstable angina, comprising a binding agent that selectively binds to a TnTuORF peptide and which binding agent can be quantatively measured upon binding to the TnTuORF peptide.

In yet a further aspect of the present invention there is provided a kit for measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from a subject with, or at risk of acquiring, a cardiac disorder other than myocardial infarction or unstable angina, comprising a binding agent that selectively binds to a TnTuORF peptide and which binding agent can be quantatively measured upon binding to TnTuORF.

In another aspect of the present invention there is provided a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds a TnTuORF peptide for use in predicting a subject's risk of acquiring a cardiac disorder other than myocardial infarction or unstable angina.

In yet a further aspect of the present invention there is provided a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds a TnTuORF peptide for use in diagnosing a cardiac disorder other than myocardial infarction or unstable angina in a subject.

In another aspect of the present invention there is provided a use of a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a TnTuORF peptide in the manufacture of a medicament for predicting a subject's risk for acquiring a cardiac disorder other than myocardial infarction or unstable angina.

In yet another aspect of the present invention there is provided a use of a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a

TnTuORF peptide in the manufacture of a medicament for diagnosing a cardiac disorder other than myocardial infarction or unstable angina in a subject.

In a further aspect of the present invention there is provided an isolated Troponin T upstream open reading frame (TnTuORF) peptide.

5 In one embodiment, the TnTuORF peptide is selected from the group of peptides set forth in any one of SEQ ID NOs: 1, 2, 3 or 4.

In another aspect of the present invention there is provided an assay for improving the sensitivity and false positive performance of cardiac troponin in predicting a subject's risk of myocardial infarction, the assay comprising a binding agent that selectively binds to
10 a Troponin T upstream open reading frame (TnTuORF) peptide and which binding agent can be quantatively measured upon binding to the TnTuORF peptide in a biological sample from the subject.

In yet a further aspect of the present invention there is provided an assay for improving the sensitivity and false positive performance of cardiac troponin in diagnosing
15 myocardial infarction in a subject, the assay comprising a binding agent that selectively binds to a Troponin T upstream open reading frame (TnTuORF) peptide and which binding agent can be quantatively measured upon binding to the TnTuORF peptide in a biological sample from the subject.

In one embodiment according to either aspect, the cardiac troponin comprises
20 Troponin T and Troponin I. In another embodiment, the assay comprises calculating the product ratio between cardiac troponin and TnTuORF peptide.

In yet a further aspect of the present invention there is provided an assay for predicting mortality in a subject following a cardiac event, the assay comprising a binding agent that selectively binds to a Troponin T upstream open reading frame (TnTuORF)
25 peptide and which binding agent can be quantatively measured upon binding to the TnTuORF peptide in a biological sample from the subject.

In yet another aspect of the present invention there is provided an assay for improving the sensitivity and false positive performance of N-terminal brain natriuretic peptide (NT-proBNP) in predicting a subject's risk of acquiring acute decompensated heart
30 failure following a cardiac event, the assay comprising a binding agent that selectively binds to a Troponin T upstream open reading frame (TnTuORF) peptide and which binding agent can be quantatively measured upon binding to the TnTuORF peptide in a biological sample from the subject.

In a further aspect of the present invention there is provided a kit for measuring the
35 level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from a subject for use in improving the sensitivity and false positive performance of cardiac troponin in predicting or diagnosing myocardial infarction in the subject, the kit comprising a binding agent that selectively binds to a TnTuORF peptide and which binding agent can be quantatively measured upon binding to TnTuORF.

In a further aspect of the present invention there is provided a kit for measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from a subject for use in improving the sensitivity and false positive performance of N-terminal brain natriuretic peptide (NT-proBNP) in predicting the subject's risk of acquiring acute decompensated heart failure following a cardiac event, the kit comprising a binding agent that selectively binds to a TnTuORF peptide and which binding agent can be quantatively measured upon binding to TnTuORF.

In yet a further aspect of the present invention there is provided a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a TnTuORF peptide in a biological sample from a subject for use in improving the sensitivity and false positive performance of cardiac troponin in predicting or diagnosing myocardial infarction in the subject.

In yet a further aspect of the present invention there is provided a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a TnTuORF peptide in a biological sample from a subject for use in predicting mortality of the subject following a cardiac event.

In yet a further aspect of the present invention there is provided a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a TnTuORF peptide in a biological sample from a subject for use in improving the sensitivity and false positive performance of N-terminal brain natriuretic peptide (NT-proBNP) in predicting the subject's risk of acquiring acute decompensated heart failure following a cardiac event.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows gene location and epitope design of TnTuORF and r244 antiserum. The major open reading frame (ORF) encoding human cardiac troponin T (NCBI Accession NG_007556) is indicated by (ATG +1 cTnT ORF). At -1512 base pairs (bp) 5' upstream from the cTnT ORF there is a uORF encoding a putative 12 amino acid peptide (TnTuORF) with the sequence MAPEGWVIVVIS. Applicants generated a polyclonal antiserum in rabbit (r244) directed to the amino terminus of TnTuORF for use in immunoassay.

Figure 2 shows representative TnTuORF immunoassay curve showing parallel dilution of human venous plasma (open circles; dilutions shown) compared with synthetic TnTuORF peptide standard curve (closed circles).

Figure 3 shows concentrations of immunoreactive (IR) TnTuORF in 109 normal, healthy volunteer plasma samples as demonstrated by a statistically significant ($r=0.201$, $P<0.05$ by Spearman Rank correlation analysis) negative correlation with Creatinine.

Figure 4 shows regional arterial-venous concentrations of IR TnTuORF (upper panel) and immunoreactive hsTnT (lower panel) in 16 patients undergoing clinically indicated

cardiac catheterisation. Venous concentrations are grey bars, whereas dark bars are time matched arterial samples for comparison of potential organ contribution to circulating levels.

FV = femoral vein, RV= renal vein, HV = hepatic vein, IVC = inferior vena cava, JUG = jugular vein, CS = cardiac coronary sinus, PA = pulmonary artery. Bars are Mean±SD, * =

5 P<0.05, ** = P<0.01 by paired *t*-test.

Figure 5 shows high performance liquid chromatography (HPLC) of immunoreactive TnTuORF in the human circulation. (A) Immunoaffinity purified TnTuORF from human plasma eluted as two peaks (I and II) on reverse phase HPLC. Peak II eluted consistent with synthetic TnTuORF peptide as indicated. Grey line indicates concentration of acetonitrile. (B) Size exclusion HPLC of immunoreactive peaks I and II from panel A revealed peak II to have an apparent Mr of ~1.5 kilodalton (k), consistent with the theoretical weight of TnTuORF (predicted Mr 1.3k). Peak I had an apparent Mr of ~1k, consistent with a carboxyl terminus shortened form. Arrows indicate molecular weight values of calibration peptides. Vt = total volume of column.

15 **Figure 6** shows concomitant immunoreactive (IR) concentrations of TnTuORF (panel A) and hsTnT (panel B) in the venous blood of 4 ST-elevation MI patients from hospital presentation to 72 hours post presentation. Data are Mean±SD.

Figure 7 shows receiver operator curve (ROC) analysis graphs of the performance of NTproBNP, TnTuORF and TnTuORF+Hb+Heart Rate (HR) variables to diagnose other cardiac conditions (n=26).

Figure 8 shows receiver operator curve (ROC) analysis graphs of the performance of hsTnT and TroponinPLUS to diagnose acute NSTEMI (n=96).

Figure 9 shows receiver operator curve (ROC) analysis graphs showing the prognostic ability of 24 hour NTproBNP and NTproBNPxTnTuORF to predict readmission with acute decompensated heart failure within one year of index admission (n=10).

DEFINITIONS

General

30 Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art to which the inventions belong (for example, in immunology, immunohistochemistry, protein chemistry, and biochemistry).

Unless otherwise indicated, the recombinant protein and immunological techniques utilized in the present invention are standard procedures well known to those skilled in the art. Such techniques are described and explained throughout the literature in sources such as, J. Perbal, *A Practical Guide to Molecular Cloning*, John Wiley and Sons (1984), J. Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press (1989), T.A. Brown (editor), *Essential Molecular Biology: A Practical Approach*,

Volumes 1 and 2, IRL Press (1991), D.M. Glover and B.D. Hames (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996), and F.M. Ausubel *et al.*, (editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including all updates until present), Ed Harlow and David Lane (editors)
5 Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, (1988), and J.E. Coligan *et al.*, (editors) Current Protocols in Immunology, John Wiley & Sons (including all updates until present).

The term "and/or", e.g., "X and/or Y" shall be understood to mean either "X and Y" or "X or Y" and shall be taken to provide explicit support for both meanings or for either
10 meaning.

Throughout this specification, unless specifically stated otherwise or the context requires otherwise, reference to a single step, composition of matter, group of steps or group of compositions of matter shall be taken to encompass one and a plurality (i.e. one or more) of those steps, compositions of matter, groups of steps or group of compositions of
15 matter.

It is intended that reference to a range of numbers disclosed herein (for example 1 to 10) also incorporates reference to all related numbers within that range (for example, 1, 1.1, 2, 3, 3.9, 4, 5, 6, 6.5, 7, 8, 9 and 10) and also any range of rational numbers within that range (for example 2 to 8, 1.5 to 5.5 and 3.1 to 4.7) and, therefore, all sub-ranges of
20 all ranges expressly disclosed herein are expressly disclosed. These are only examples of what is specifically intended and all possible combinations of numerical values between the lowest value and the highest value enumerated are to be considered to be expressly stated in this application in a similar manner.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or
25 step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to
30 be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features.

The present invention is not to be limited in scope by the specific embodiments
35 described herein, which are intended for the purpose of exemplification only. Functionally-equivalent products, compositions and methods are clearly within the scope of the invention, as described herein.

Any embodiment herein shall be taken to apply *mutatis mutandis* to any other embodiment unless specifically stated otherwise.

Selected Definitions

Throughout this specification, the term "TnTuORF" means a Troponin T upstream open reading frame peptide. In this specification the terms "TnTuORF" and "TnTuORF peptide" are used interchangeably, and are intended to mean any peptide which exists in circulation as a discrete chemical entity, and is encoded for by an upstream open reading frame of the Troponin T gene.

The term "cardiac disorder other than acute myocardial infarction or unstable angina" according to the present invention includes any cardiac disorder other than myocardial infarction or unstable angina, and includes, for example, atrial fibrillation, heart failure, pericarditis, disorders of nerve conduction and combinations thereof.

The term "biological sample" as used herein includes biological fluids selected from blood including venous blood and arterial blood, plasma, serum, interstitial fluid, or any other body fluid. The term "biological sample" also includes heart tissue sample. The term "biological sample" and "body fluid sample" as used herein refers to a biological sample or a sample of bodily fluid obtained for the purpose of, for example, diagnosis, prognosis, classification or evaluation of a subject of interest, such as a patient. In certain embodiments, such a sample may be obtained for diagnosing a cardiac disorder other than myocardial infarction or unstable angina, for performing risk stratification of a cardiac disorder other than myocardial infarction or unstable angina, for making a prognosis of a disease course in a patient with a cardiac disorder other than myocardial infarction or unstable angina, for identifying a patient with elevated risk of a cardiac disorder other than myocardial infarction or unstable angina, or combinations thereof. In addition, one of skill in the art would realise that certain body fluid samples would be more readily analysed following a fractionation or purification procedure, for example, separation of whole blood into serum or plasma components.

The term "level" as used herein is intended to refer to the amount per weight or weight per weight of TnTuORF. It is also intended to encompass "concentration" expressed as amount per volume or weight per volume. The term "circulating level" is intended to refer to the amount per weight or weight per weight or concentration of a TnTuORF peptide present in the circulating fluid.

An "increase" or "decrease" in the circulating level of a TnTuORF peptide (or any other biomarker for that matter) compared with a control, or a "change" or "deviation" from a control (level) in one embodiment is statistically significant. A increased level, decreased level, deviation from, or change from a control level or mean or historical control level can be considered to exist if the level differs from the control level by about 5% or more, by about 10% or more, by about 20% or more, or by about 50% or more compared to the control level. Statistically significant may alternatively be calculated as $P \leq 0.05$. Increased levels, decreased levels, deviation, and changes can also be determined by recourse to assay reference limits or reference intervals. These can be calculated from intuitive

assessment or non-parametric methods. Overall, these methods may calculate the 0.025, and 0.975 fractiles as $0.025 * (n+1)$ and $0.975 * (n+1)$. Such methods are well known in the art. Presence of a marker absent in a control may be seen as a higher level, deviation or change. Absence of a marker present in a control may be seen as a lower level, deviation or change.

Specifically, the term "reference interval" as used herein is intended to refer to a figure within a statistical band of a representative concentration or alternatively a figure with an upper or lower concentration. The reference interval will typically be obtained from subjects that do not have any pre-existing conditions that could result in artificially elevating the level of circulating TnTuORF. These conditions are discussed elsewhere herein.

The term "delta %" as used herein is understood to refer to a percentage change in a given variable (i.e. the level or concentration of TnTuORF peptide). The delta % is determined by taking the final concentration of TnTuORF peptide in a biological sample, subtracting the initial concentration of TnTuORF peptide and dividing it by the initial concentration of TnTuORF peptide where the result is presented as a percentage. Thus, by way of non-limiting example, an increase of 300 pmol/mL from an initial concentration of 800 pmol/mL represents a 37.5% change.

For the sake of clarity, an increase of 31-39 delta % includes for example, 31, 32, 33, 34, 35, 36, 37, 38 or 39 delta % increase, as well as fractions there between.

The term "subject" as used herein is intended to refer to a human or non-human primate. In one embodiment, the subject is a human.

The term "suitable control population" according to the present invention refers to the mean circulating TnTuORF peptide level from sex- and age-matched subjects for which cardiac disorder information is known. The control population is used to provide a suitable reference interval by which a measured TnTuORF peptide level is compared.

The term "binding agent" as used herein is intended to refer to any molecule that binds TnTuORF peptides, including small molecules, antibodies from any species whether polyclonal or monoclonal, antigen-binding fragments such as Fab and Fab₂, humanized antibodies, chimeric antibodies, or antibodies modified in other ways including substitution of amino acids, and/or fusion with other peptides or proteins (e.g. PEG). It also includes receptors or binding proteins from any species or modified forms of them. In one example, the binding agent specifically binds to TnTuORF.

The term "specifically binds" as used herein shall be taken to mean that the binding agent reacts or associates more frequently, more rapidly, with greater duration and/or with greater affinity to a particular substance than it does with alternative substances. For example, a binding agent that specifically binds to TnTuORF binds that protein or an epitope or immunogenic fragment thereof with greater affinity, avidity, more readily, and/or with greater duration than it binds to unrelated protein and/or epitopes or immunogenic

fragments thereof. It is also understood by reading this definition that, for example, a binding agent that specifically binds to a first target (e.g. TnTuORF) may or may not specifically bind to a second target. As such, "specific binding" does not necessarily require exclusive binding or non-detectable binding of another molecule. Generally, but not necessarily, reference to binding means specific binding.

The term "antibody" refers to an immunoglobulin molecule capable of specifically binding to a target, such as TnTuORF by virtue of an antigen binding site contained within at least one variable region. This term includes four chain antibodies (e.g., two light chains and two heavy chains), recombinant or modified antibodies (e.g., chimeric antibodies, humanized antibodies, primatized antibodies, de-immunized antibodies, half antibodies, bispecific antibodies) and single domain antibodies such as domain antibodies and heavy chain only antibodies (e.g., camelid antibodies or cartilaginous fish immunoglobulin new antigen receptors (IgNARs)). An antibody generally comprises constant domains, which can be arranged into a constant region or constant fragment or fragment crystallisable (Fc). Preferred forms of antibodies comprise a four-chain structure as their basic unit. Full-length antibodies comprise two heavy chains (~50-70 kDa) covalently linked and two light chains (~23 kDa each). A light chain generally comprises a variable region and a constant domain and in mammals is either a κ light chain or a λ light chain. A heavy chain generally comprises a variable region and one or two constant domain(s) linked by a hinge region to additional constant domain(s). Heavy chains of mammals are of one of the following types α , δ , ϵ , γ , or μ . Each light chain is also covalently linked to one of the heavy chains. For example, the two heavy chains and the heavy and light chains are held together by inter-chain disulfide bonds and by non-covalent interactions. The number of inter-chain disulfide bonds can vary among different types of antibodies. Each chain has an N-terminal variable region (V_H or V_L wherein each are ~110 amino acids in length) and one or more constant domains at the C-terminus. The constant domain of the light chain (C_L which is ~110 amino acids in length) is aligned with and disulfide bonded to the first constant domain of the heavy chain (C_H which is ~330-440 amino acids in length). The light chain variable region is aligned with the variable region of the heavy chain. The antibody heavy chain can comprise 2 or more additional C_H domains (such as, C_{H2} , C_{H3} and the like) and can comprise a hinge region can be identified between the C_{H1} and C_m constant domains. Antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁ and IgA₂) or subclass. In one example, the antibody is a murine (mouse or rat) antibody or a primate (preferably human) antibody. The term "antibody" encompasses not only intact polyclonal or monoclonal antibodies, but also variants, fusion proteins comprising an antibody portion with an antigen binding site, humanised antibodies, human antibodies, chimeric antibodies, primatised antibodies, de-immunised antibodies or veneered antibodies.

The term "antigen binding fragment" shall be taken to mean any fragment of an antibody that retains the ability to bind to TnTuORF and preferably one which specifically binds to TnTuORF. This term includes a Fab fragment, a Fab' fragment, a F(ab') fragment, a single chain antibody (SCA or SCAB) amongst others. An "Fab fragment" consists of a monovalent antigen-binding fragment of an antibody molecule, and can be produced by digestion of a whole antibody molecule with the enzyme papain, to yield a fragment consisting of an intact light chain and a portion of a heavy chain. An "Fab' fragment" of an antibody molecule can be obtained by treating a whole antibody molecule with pepsin, followed by reduction, to yield a molecule consisting of an intact light chain and a portion of a heavy chain. Two Fab' fragments are obtained per antibody molecule treated in this manner. An "F(ab')₂ fragment" of an antibody consists of a dimer of two Fab' fragments held together by two disulfide bonds, and is obtained by treating a whole antibody molecule with the enzyme pepsin, without subsequent reduction. An "Fv fragment" is a genetically engineered fragment containing the variable region of a light chain and the variable region of a heavy chain expressed as two chains. A "single chain antibody" (SCA) is a genetically engineered single chain molecule containing the variable region of a light chain and the variable region of a heavy chain, linked by a suitable, flexible polypeptide linker.

The term "chimeric antibody" refers to antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species (e.g., murine, such as mouse) or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species (e.g., primate, such as human) or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; and Morrison *et al.* (1984) *Proc. Natl Acad. Sci USA* 81:6851-6855).

The term "humanized antibody" shall be understood to refer to a chimeric molecule, generally prepared using recombinant techniques, having an epitope binding site derived from an immunoglobulin from a non-human species and the remaining immunoglobulin structure of the molecule based upon the structure and/or sequence of a human immunoglobulin. The antigen-binding site preferably comprises the complementarity determining regions (CDRs) from the non-human antibody grafted onto appropriate framework regions in the variable domains of human antibodies and the remaining regions from a human antibody. Epitope binding sites may be wild type or modified by one or more amino acid substitutions. It is known that the variable regions of both heavy and light chains contain three complementarity-determining regions (CDRs) which vary in response to the epitopes in question and determine binding capability, flanked by four framework regions (FRs) which are relatively conserved in a given species and which putatively provide a scaffolding for the CDRs. When nonhuman antibodies are prepared with respect to a

particular epitope, the variable regions can be "reshaped" or "humanized" by grafting CDRs derived from nonhuman antibody on the FRs present in the human antibody to be modified.

The term "epitope" includes any antigenic (e.g., a protein) determinant capable of specific binding to an antibody and/or a T cell receptor. That is, a site on an antigen to which B and/or T cells respond. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains, and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. An epitope typically includes, for example, at least 3, 5 or 8-10 amino acids. The amino acids may be contiguous, or non-contiguous amino acids juxtaposed by tertiary folding. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.

As used herein, the term "antigenic variant" refers to polypeptide sequences different from the specifically identified sequences, wherein one or more amino acid residues are deleted, substituted, or added. Substitutions, additions or deletions of 1, 2, 3 or 4 amino acids are specifically contemplated. Variants may be naturally-occurring allelic antigenic variants, or non-naturally occurring antigenic variants. Variants may be from the same or from other species and may encompass homologues, paralogues and orthologues. In certain embodiments, antigenic variants of the polypeptides useful in the invention have biological activities including hormone function or antigenic-binding properties that are the same or similar to those of the parent polypeptides. The term "antigenic variant" with reference to (poly)peptides encompasses all forms of polypeptides as defined herein. The term "antigenic variant" encompasses naturally occurring, recombinantly and synthetically produced polypeptides.

In addition to computer/database methods known in the art, polypeptide antigenic variants may be identified by physical methods known in the art, for example, by screening expression libraries using antibodies raised against polypeptides of the invention (Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor Press, 1987) by recombinant DNA techniques also described by Sambrook *et al.* or by identifying polypeptides from natural sources with the aid of such antibodies.

DETAILED DESCRIPTION

The use of Troponin T upstream open reading frame (TnTuORF) peptides and binding agents described herein in assays, methods and kits for the prognosis or diagnosis of cardiac disorders other than myocardial infarction or unstable angina are of clear clinical significance in detecting early onset of, for example, atrial fibrillation, heart failure, pericarditis, disorders of nerve conduction, vasovagalsyncope and combinations thereof (defined in Thygesen *et al.* (2012) *Circulation* 126:2020-2035; Table I on page 2024). The inventions described herein provide the clinician with the ability to stratify subjects who may be potentially at risk of a cardiac disorder or worsening of an existing cardiac disorder.

Additionally, the methods, assays and kits of the present disclosure provide the clinician with a means to monitor a subject's responsiveness to existing therapy. For example, by measuring the TnTuORF levels in a subject over time, the clinician can monitor a subject's response to therapy or treatment.

Further, the present invention is drawn to assays, methods and kits involving binding agents specific for TnTuORF peptides for improving the sensitivity and false positive performance of cardiac troponins in predicting or diagnosing myocardial infarction, for improving the sensitivity and false positive performance of NT-proBNP in predicting a subject's risk of hospital readmission with acute decompensated heart failure following a cardiac event, and in predicting the mortality of a subject following a cardiac event.

The inventions described herein will become apparent having regard to the following detailed description.

TnTuORF peptide is present in human circulation

Applicants initially sought to confirm their hypothesis that a peptide encoded for by an upstream open reading frame of a cardiac troponin exists as a distinct and discrete biomarker in circulation, and in particular in human plasma.

Following detailed bioinformatic analysis of the cardiac troponin genes, Applicants identified an open reading frame (ORF) located -1512 bp (i.e. upstream) of the major initiating codon for cardiac Troponin T (Figure 1). With a Kozak score of +2 and high likelihood of being translated, Applicants predicted that this upstream open reading frame (uORF) should encode a putative 12 amino acid peptide and sought to confirm its existence using immunohistochemistry.

Applicants initially raised a polyclonal antibody directed toward the amino terminus of the putative 12 amino acid peptide with a predicted sequence of MAPEGWVIVVIS (SEQ ID NO:1). This antibody (r244) displayed little or no cross-reactivity to other known and established circulating peptides and/or drugs, and importantly including, for example, Cardiac Troponin T and Cardiac Troponin I, N-terminal brain natriuretic peptide (NT-proBNP) and the mature form of brain natriuretic peptide (BNP; Table III in Example 2).

The r244 polyclonal antibody was then used to develop a sensitive and specific radioimmunoassay. Figure 2 shows a representative TnTuORF immunoassay curve indicating parallel dilution of human venous plasma (obtained from peripheral blood of healthy adult subjects) compared to the synthetic TnTuORF peptide standard curve. These data provide the first direct evidence to demonstrate the existence of a peptide, encoded for by an upstream open reading frame coding sequence, in this case a uORF of Troponin T, which exists as a distinct chemical entity in circulation.

Further, and importantly, TnTuORF had no significant association with high sensitivity Troponin T (hsTnT) levels, age, blood pressure and body mass index.

Applicants next sought to identify the TnTuORF species detected by immunoassay through reverse phase high performance liquid chromatography (RP-HPLC) and size exclusion high performance liquid chromatography (SE-HPLC) coupled to immunoassay (Figure 5). The results of these analyses confirmed that the immunoreactive TnTuORF is present in human plasma as (i) an intact 12 amino acid peptide (i.e. MAPEGWVIVVIS; SEQ ID NO: 1) and (ii) carboxy terminus shortened forms, including but not limited to MAPEGWVIVVI (SEQ ID NO: 2), MAPEGWVIVV (SEQ ID NO: 3) and MAPEGWVIV (SEQ ID NO:4).

10 **TnTuORF as a biomarker of cardiac disorders**

Having established that immunoreactive TnTuORF is in fact present in human circulation, Applicants then sought to determine its potential clinical utility in cardiac disorders, including acute coronary syndromes. Initially, patients from four separate cohorts were recruited, namely, (i) healthy volunteers with no evidence or history of cardiovascular, endocrine or psychiatric illness (n=109), (ii) patients undergoing clinically indicated cardiac catheterisation (n=16), (iii) patients with documented ST-elevation myocardial infarction (n=4) and an acute coronary syndromes cohort (n=502). Details on the extent of blood sampling from these different patient cohorts are described in methods section in Example 1.

The initial set of measurements involved looking at potential clinical utility of circulating TnTuORF peptide as a diagnostic biomarker of acute cardiac ischemia resulting in myocardial infarction (i.e patient cohort (iii)). Figure 5A shows that venous concentrations of TnTuORF peptide tended to decrease in the first 4-5 hours after symptom onset and although there was a general increase back to a plateau at about 24hrs, the levels of TnTuORF were in fact less than half those observed in normal controls (Example 5). Compared with hsTnT, in which the concentration of this marker rises sharply in plasma of STEMI patients in the acute phase following an ischemic event (Figure 5B), these data do not support the clinical utility of TnTuORF peptide in diagnosing acute cardiac ischemia resulting in myocardial infarction.

To assess the potential utility of TnTuORF peptide in predicting or diagnosing other cardiac disorders, including acute coronary syndromes (Thygesen *et al.* (2012) *Circulation* 126:2020-2035), Applicants undertook a prospective, observational study of 502 patients presenting to the Emergency Department (ED) with the primary complaint of chest pain of suspected cardiac origin for which patient demographic and analyte data are presented in Table II (Example 1). The results of the various analyses confirmed that TnTuORF peptide plasma concentrations in patients presenting to ED had utility in the diagnosis of cardiac disorders other than myocardial infarction (MI) and unstable angina (UA; Figure 7).

As such, Applicants have surprisingly found that in patients with a cardiac disorder other than myocardial infarction or unstable angina the circulating concentration of

TnTuORF peptide is highest in the first twelve hours following the onset of the patient's symptoms. Levels observed in the first twelve, ten, eight, six, four, two or one hours of onset of, or at clinical presentation with the disorder hours were surprisingly high, often reaching up to 2-fold, 3-fold, 4-fold and 5-fold, and commonly 1.5-fold higher than levels in a normal control population.

In sum, one or more TnTuORF peptides is/are useful as clear early stage markers of, for example, cardiac disorders other than myocardial infarction or unstable angina, including, for example, atrial fibrillation, heart failure, pericarditis, disorders of nerve conduction and combinations thereof, as well as other disorders as noted herein.

Based on these surprising findings, Applicants have determined for the first time, that it would be useful to screen for one or more TnTuORF peptides or fragments thereof in a biological sample taken from a subject, particularly, for example, within twelve, ten, eight, six, four, two or one hours of onset of, or at clinical presentation with the disorder.

Accordingly, in one aspect of the present invention there is provided a method of predicting a subject's risk of acquiring a cardiac disorder other than myocardial infarction or unstable angina, the method comprising:

(i) measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from the subject; and

(ii) comparing the measured level of the TnTuORF peptide against a reference interval from a suitable control population,

wherein an increase in the circulating level of the TnTuORF peptide compared with the control population is predictive of acquiring a cardiac disorder other than myocardial infarction or unstable angina, and further wherein the measuring step comprises detecting binding between the TnTuORF peptide and a binding agent that selectively binds to the TnTuORF peptide.

In another aspect of the present invention there is provided a method of diagnosing a cardiac disorder other than myocardial infarction or unstable angina in a subject, the method comprising:

(i) measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from the subject; and

(ii) comparing the measured level of the TnTuORF peptide against a reference interval from a suitable control population,

wherein an increase in the circulating level of the TnTuORF peptide compared with the control population is indicative of a cardiac disorder other than myocardial infarction or unstable angina, and further wherein the measuring step comprises detecting binding between the TnTuORF peptide and a binding agent that selectively binds to the TnTuORF peptide.

The skilled reader will appreciate that for evaluation purposes, the level of TnTuORF peptide may usefully be compared or correlated with a reference value or control value. In

one embodiment the control population is sex and age-matched subjects for which the cardiac disorder is known.

As used herein a control population can be an individual or group from which samples of a TnTuORF peptide are taken and a mean level determined. Usually, the individual or group will comprise normal healthy individuals or a group of individuals not known to be suffering from a cardiac disorder. In one embodiment, the reference interval is the mean circulating TnTuORF peptide concentration from the control population. Levels of TnTuORF peptides in control populations range from between about 430-1130 pg/mL, with a mean of about 778 pg/mL ($P < 0.001$). Alternatively, the control population may be assessed based on a plurality of readings from previously tested individuals or groups. Levels in the order of 730-1590 pg/mL, with a mean of about 1159 pg/mL are typically indicative of a cardiac disorder other than myocardial infarction or unstable angina.

It will be appreciated that the step of measuring levels of TnTuORF peptides in a sample may be a single measurement on a single sample, or repeated measurements on a number of samples depending on the biological event being studied. In the case of a cardiac disorder, measurement may comprise, for example, 1 to 20 or more measurements of TnTuORF peptide, 1 to 10, 1 to 5, 1 to 3, or 2 or 3 measurements of a TnTuORF peptide in samples taken at different times. In one embodiment the measurements are on samples taken within the first twelve, ten, eight, six, five, four, two hours, or within one hour or less of, onset of or clinical presentation with a disorder or suspected disorder. Single, or repeated measurements outside the sample period above may also be taken to establish whether the level of a TnTuORF peptide has fallen to the normal control level, or, for example, cardiac tissue control level.

The assays, methods and kits of the present invention comprise measuring levels of a TnTuORF peptide in one or two samples taken within the first hour of onset or presentation, followed by measuring levels of a TnTuORF peptide in one or two samples taken within two to four hours, or two to three hours of onset or presentation, or initial measurement of the level of a TnTuORF peptide.

Accordingly, in certain embodiments, the method of predicting a subject's risk of acquiring a cardiac disorder other than myocardial infarction or unstable angina or the method of diagnosing a cardiac disorder other than myocardial infarction or unstable angina in a subject further comprises measuring the level of the TnTuORF peptide in a first biological sample from the subject and measuring the level of the TnTuORF peptide in a second biological sample, wherein the second biological sample is taken from the same subject as the first biological sample but at a later period in time, and comparing the levels of TnTuORF peptide in the first and second samples, wherein an increase in the circulating level of TnTuORF peptide between the first and second samples is indicative of increased risk to acquiring the cardiac disorder.

As noted above, levels of a TnTuORF peptide may be measured within the first one to twelve, ten, eight, six, four or two hours or less of onset or presentation of a cardiac disorder and are, for example, 1.5-5-fold higher than levels measured in a normal control.

The biological sample as defined above can be any biological material in which a TnTuORF peptide can be located or secreted. In one embodiment a biological sample is a circulatory biological sample, for example venous blood and arterial blood, plasma, serum or interstitial fluid. In another embodiment, the biological sample is cardiac tissue or heart tissue sample.

The term "measuring the level of a TnTuORF peptide" in a biological sample refers to methodologies that enable the determination of TnTuORF peptide level or concentration in the sample, such as, for example an immunoassay including radioimmunoassay, enzyme linked immunosorbent assay (ELISA), immunofluorometric assay and immunoradiometric assay, as will be known to a person skilled in the art. In one example, the TnTuORF peptide level is expressed as pg/mL. The terms TnTuORF peptide level and TnTuORF peptide concentration may be used interchangeably.

In the assays, methods and kits according to the present invention, the measuring steps comprise detecting binding between a TnTuORF peptide and a binding agent that binds, selectively or specifically, to the TnTuORF peptide, and has low cross-reactivity with other markers of biological events. In certain embodiments, the binding agent is an antibody or an antigen-binding fragment thereof. The antibody may be a monoclonal, polyclonal, chimeric or humanized antibody or antigen-binding fragment thereof. In other embodiments, the binding agent or antibody may be immobilised to a solid phase. A more detailed description of binding agents, including antibodies and antigen-binding fragments, is outlined elsewhere in this specification.

The specificity and sensitivity of TnTuORF peptide in predicting or diagnosing cardiac disorders other than myocardial infarction or unstable angina was further improved when the concentration of TnTuORF was added to heart rate values and haemoglobin concentration. By way of illustration, and in reference to Figure 7, when TnTuORF was added to heart rate and Hb concentration, the diagnosis of cardiac disorders other than myocardial infarction and unstable angina improved from AUC = 0.79 ($P < 0.001$) to AUC = 0.83 ($P < 0.001$). Accordingly, in certain embodiments of the present invention, the assays, methods and kits for predicting or diagnosing a cardiac disorder of the present invention may also be performed in conjunction with the analysis of one or more risk factors such as, for example, heart rate, haemoglobin concentration, blood pressure, age, sex, weight, level of physical activity, family history of events including obesity, diabetes and cardiac events, and circulating levels of Troponin T and Troponin I.

With respect to the "AUC" values referred to above, and as described in the Examples which follow with regard to TnTuORF peptides and their ability to predict or diagnose a subject with a cardiac disorder, population studies may also be used to select a

decision threshold. Receiver Operating Characteristic ("ROC") arose from the field of signal detection theory developed during World War II for the analysis of radar images, and ROC analysis is often used to select a threshold able to best distinguish a "diseased" subpopulation from a "nondiseased" subpopulation. A false positive in this case occurs when the person tests positive, but actually does not have the disease. A false negative, on the other hand, occurs when the person tests negative, suggesting they are healthy, when they actually do have the disease. To draw a ROC curve, the true positive rate (TPR) and false positive rate (FPR) are determined as the decision threshold is varied continuously. Since TPR is equivalent with sensitivity and FPR is equal to 1-specificity, the ROC graph is sometimes called the sensitivity vs (1-specificity) plot. A perfect test will have an area under the (ROC) curve (i.e. AUC) of 1.0; a random test will have an area of 0.5. A threshold is selected to provide an acceptable level of specificity and sensitivity.

As described above, the methods, assays and kits of the present disclosure provide the clinician with a means to monitor a subject's responsiveness to existing therapy.

Accordingly, in another embodiment of the present invention, the methods for predicting or diagnosing a subject with a cardiac disorder other than myocardial infarction or unstable angina further comprise administering a treatment regimen to the subject where the subject is found to have an increase in a circulating level of the TnTuORF peptide compared with the circulating level of the TnTuORF peptide in the control population.

Further, in yet another aspect of the present invention there is provided for monitoring the responsiveness of a subject to treatment with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina, the method comprising:

- (i) measuring the level of TnTuORF in a first biological sample from the subject;
- (ii) measuring the level of TnTuORF in a second biological sample from the subject, wherein the second biological sample is taken from the same subject; and
- (iii) comparing the measured levels of TnTuORF in the first and second samples, wherein an increase in the level of TnTuORF between the first and second samples is indicative of a poor response to treatment with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina and wherein a decrease in the level of TnTuORF between the first and second samples is indicative of a positive response to a treatment with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina.

Contingent on the cardiac disorder to be treated, it is possible that an increased level of TnTuORF peptide between the first and second samples is indicative of a positive response to treatment with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina. Put another way, a decreased level of TnTuORF peptide between the first and second samples is indicative of a poor response to treatment with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina.

Accordingly, in yet a further aspect of the present invention there is provided a method for monitoring the responsiveness of a subject to treatment with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina, the method comprising:

- 5 (i) measuring the level of a TnTuORF peptide in a first biological sample from the subject;
- (ii) measuring the level of a TnTuORF peptide in a second biological sample from the subject, wherein the second biological sample is taken from the same subject; and
- 10 (iii) comparing the measured levels of the TnTuORF peptide in the first and second samples,

wherein a decrease in the level of TnTuORF peptide between the first and second samples is indicative of a poor response to treatment with a with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina and wherein an
15 increase in the level of TnTuORF peptide between the first and second samples is indicative of a positive response to a to treatment with a with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina.

Where a subject is to be monitored, a number of biological samples may be taken over time. Serial sampling allows changes in marker levels to be measured over time.
20 Sampling can provide information on the approximate onset time of an event, the severity of the event, indicate which therapeutic regimes may be appropriate, response to therapeutic regimes employed, or long term prognosis. Analysis may be carried out at points of care such as in ambulances, doctors' offices, on clinical presentation, during hospital stays, in outpatients, or during routine health screening, etc.

25 Again, the method may also be performed in conjunction with the analysis of one or more risk factors of cardiac disorders such as, for example, heart rate, haemoglobin concentration, blood pressure, age, sex, weight, level of physical activity, family history of events including obesity, diabetes and cardiac events, and circulating levels of Troponin T and Troponin I.

30 Finally, a person skilled in the art will appreciate that the present invention is also directed to the specific TnTuORF peptide binding members, as well as their use in the manufacture of medicaments for predicting or diagnosing a subject with, or at risk of developing, a cardiac disorder other than myocardial infarction or unstable angina.

Accordingly, the present invention also provides a Troponin T upstream open reading
35 frame (TnTuORF) peptide binding agent that selectively binds TnTuORF peptide for use in predicting a subject's risk of acquiring a cardiac disorder other than myocardial infarction or unstable angina.

The present invention further provides a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds TnTuORF peptide for use in

diagnosing a cardiac disorder other than myocardial infarction or unstable angina in a subject.

The present invention also provides a use of a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a TnTuORF peptide in the manufacture of a medicament for predicting a subject's risk for acquiring a cardiac disorder other than myocardial infarction or unstable angina.

The present invention further provides a use of a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a TnTuORF peptide in the manufacture of a medicament for diagnosing a cardiac disorder other than myocardial infarction or unstable angina in a subject.

TnTuORF as a biomarker of myocardial infarction

Despite its lack of utility in being able to directly predict or diagnose acute cardiac ischemia resulting in myocardial infarction, surprisingly, Applicants demonstrate that TnTuORF peptide improves the sensitivity and false positive performance of existing cardiac troponin biomarkers in predicting and/or diagnosing myocardial infarction. In absolute terms, the product ratio of Troponin I x hsTroponin T / TnTuORF (herein referred to as TroponinPLUSTM) increased by 4% the number of myocardial infarction patients detected within 2 hours (i.e. 94/96 NSTEMI patients or 98%; compared with hsTnT which detected 90/96 NSTEMI patients or 90% and TnI which detected 88/96 NSTEMI patients or 92%) and reduced the false positive diagnosis rate by 7% (Example 6; Figure 8).

Accordingly, in a further aspect of the present invention there is provided an assay for improving the sensitivity and false positive performance of cardiac troponin in predicting a subject's risk of myocardial infarction, the assay comprising a binding agent that selectively binds to a Troponin T upstream open reading frame (TnTuORF) peptide and which binding agent can be quantatively measured upon binding to the TnTuORF peptide in a biological sample from the subject.

The invention further provides an assay for improving the sensitivity and false positive performance of cardiac troponin in diagnosing myocardial infarction in a subject, the assay comprising a binding agent that selectively binds to a Troponin T upstream open reading frame (TnTuORF) peptide and which binding agent can be quantatively measured upon binding to the TnTuORF peptide in a biological sample from the subject.

In one embodiment according to either aspect, the cardiac troponin comprises Troponin T and Troponin I. In an example, the cardiac troponin can be represented by highly sensitivity Troponin T (hsTnT) x Troponin I. In another embodiment, the sensitivity and false positive performance of cardiac troponin is improved by taking the product ratio of cardiac troponin to TnTuORF peptide. In an example the product ratio is represented by hsTnT x TnI / TnTuORF. As described above, this product ratio increases the sensitivity and

false positive performance of cardiac troponin in predicting or diagnosing myocardial infarction.

The present invention also provides a kit for measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from a subject for use in improving the sensitivity and false positive performance of cardiac troponin in predicting or diagnosing myocardial infarction in the subject, the kit comprising a binding agent that selectively binds to a TnTuORF peptide and which binding agent can be quantatively measured upon binding to TnTuORF.

In one embodiment, the kit further comprises instructions for how to measure the level of TnTuORF peptide.

The present invention further provides a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a TnTuORF peptide in a biological sample from a subject for use in improving the sensitivity and false positive performance of cardiac troponin in predicting or diagnosing myocardial infarction in the subject.

Furthermore, with respect to prognosis, TroponinPLUS™ (i.e. hsTnT x TnI / TnTuORF) predicted mortality at 1 year (AUC = 0.74, $P < 0.001$), more accurately than hsTnT and TnI alone (AUC = 0.72 and 0.71, respectively) but did not improve on either Troponin T or Troponin I to predict readmission with myocardial infarction or chronic heart failure within one year.

Accordingly, in yet a further aspect of the present invention there is provided an assay for predicting mortality in a subject following a cardiac event, the assay comprising a binding agent that selectively binds to a Troponin T upstream open reading frame (TnTuORF) peptide and which binding agent can be quantatively measured upon binding to the TnTuORF peptide in a biological sample from the subject.

In one embodiment, the assay can be used to predict mortality in the subject up to 9 months, 10 months, 11 months, 12 months, 13 months, 14 months and 15 months following the cardiac event, and more commonly 12 months following the cardiac event.

The present invention further provides a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a TnTuORF peptide in a biological sample from a subject for use in predicting mortality of the subject following a cardiac event.

Addition of single inpatient 24 hour TnTuORF concentration to matched NTproBNP improved the ROC curve for 24 hour NTproBNP alone to predict readmission with acute decompensated heart failure (ADHF) around one year (AUC = 0.93 vs. 0.91; Figure 9).

Accordingly, in a further aspect of the present invention there is provided an assay for improving the sensitivity and false positive performance of N-terminal brain natriuretic peptide (NT-proBNP) in predicting a subject's risk of acquiring acute decompensated heart failure following a cardiac event, the assay comprising a binding agent that selectively binds to a Troponin T upstream open reading frame (TnTuORF) peptide and which binding agent

can be quantatively measured upon binding to the TnTuORF peptide in a biological sample from the subject.

In one embodiment, the assay can be used to predict a subject's risk of acquiring acute decompensated heart failure following a cardiac event up to 9 months, 10 months, 11 months, 12 months, 13 months, 14 months and 15 months following the cardiac event, and more commonly 12 months following the cardiac event

The present invention further provides a kit for measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from a subject for use in improving the sensitivity and false positive performance of N-terminal brain natriuretic peptide (NT-proBNP) in predicting the subject's risk of acquiring acute decompensated heart failure following a cardiac event, the kit comprising a binding agent that selectively binds to a TnTuORF peptide and which binding agent can be quantatively measured upon binding to TnTuORF.

Finally, the present invention also provides a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a TnTuORF peptide in a biological sample from a subject for use in improving the sensitivity and false positive performance of N-terminal brain natriuretic peptide (NT-proBNP) in predicting the subject's risk of acquiring acute decompensated heart failure following a cardiac event.

Binding agents to TnTuORF

TnTuORF peptides are measured in a body fluid sample by detecting binding between a TnTuORF peptide and a binding agent that selectively binds to the TnTuORF peptide. Binding agents for use in the methods of the present disclosure preferably have low cross-reactivity, for example with ANP and BNP. The binding agents may include antibodies or antigen-binding fragments such as Fab and F(ab)₂, prepared using antigenic TnTuORF peptides or fragments thereof as immunising antigens. The polypeptide or fragments may also be coupled to a carrier as described. In one example, the binding agent is an antibody. The antibody may be a monoclonal or polyclonal antibody. Methods for producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (for example see Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, New York 1988), but have also been developed in-house by Applicants (e.g. Siriwardena *et al.* (2010) *Circulation* 122:255-264). For reasons of specificity, monoclonal antibodies are preferred. It will be appreciated by a person skilled in the art that humanised antibodies are not required for in vitro assays.

In one example, the antibody is raised against an antigenic TnTuORF peptide. In one example, the antigenic TnTuORF peptide comprises MAPEGWVIVVIS (SEQ ID NO: 1), MAPEGWVIVVI (SEQ ID NO: 2), MAPEGWVIVV (SEQ ID NO: 3) or MAPEGWVIV (SEQ ID NO: 4). This generally provides a sufficient epitope for specific amino acid detection.

Monoclonal antibodies may be produced by known art methods. These include the immunological method described by Kohler et al (1975) Nature 256(5517):495-7 as well as the recombination DNA method described by Huse et al (1989) 246(4935):1275-81. The use of recombinant phage antibody systems to produce single chain variable antibody fragments, and subsequent mutation (such as site specific mutagenesis) or chain shifting to produce antibodies to NT-CNP peptides is also contemplated.

Conventional procedures for generating polyclonal antibodies are detailed in Harlow and Lane (*supra*). Briefly, the protocol requires immunisation of a selected animal host such as a rabbit, goat, donkey, sheep, rat or mouse (usually a rabbit), with an isolated NT-CNP peptide on a number of spaced occasions, with one or more test bleeds preceding exsanguination and blood collection. Serum may be separated from clotted blood by centrifugation. Serum may be tested for the presence of polyclonal antibodies using ELISA or radioimmunoassay competitive assays or art equivalent methods.

Antibodies specific to TnTuORF can be raised after first conjugating these or similar peptides to a large protein such as limpet hemocyanin (KLH), bovine serum albumin (BSA) or bovine thyroglobulin to make them immunogenic. Coupling can be effected by use of any protein crosslinking agent including for example the common agents glutaraldehyde, carbodiimide or N-(ε-maleimido-caproyloxy) succinimide ester (MCS)—providing a cysteine residue is added to the peptide sequence prior to coupling. Injection of these conjugates into rabbits, sheep, mice or other species at monthly intervals followed by collection of blood samples two weeks later will enable production of polyclonal antibodies or monoclonal antibodies from the spleens of mice.

For example, the mouse host described above may be sacrificed and its spleen removed. The messenger RNA (mRNA) are then isolated and cDNA made from the mRNA using specific primers for the heavy and light chains of the variable region of the antibodies and the polymerase chain reaction (PCR) amplification. The DNA sequences for the heavy and light chains are joined with a linker sequence, to ensure the correct reading frame. Then the DNA construct is inserted into a vector, for example, a plasmid or bacteriophage, or virus, for transformation into a host. In one example the vector is a bacteriophage.

Suitable hosts may be selected from prokaryotic, yeast, insect or mammalian cells. In one example, a prokaryotic host, preferably *Escherichia coli* is used. The bacteriophage produces a viral coat and the antibody fragments are expressed on the coat, a phage display library. The phage display library can be screened for antibody fragments with the appropriate affinity for the specific antigens. The library can be screened many times and modifications can be made to the antibody construct through protein engineering techniques, such as site directed mutagenesis and chain shuffling all of which are within the capabilities of the person skilled in the art.

Detection of binding agents including peptide binding assays

The present invention includes use of a detection system involving the binding of TnTuORF peptides to a binding agent and then detecting the amount of bound peptide. A similar solution is to detect the amount of unbound binding agent in a sample to get an indication of unbound or bound TnTuORF. It is intended that such alternative methods fall within the scope of the present invention as functional alternatives to directly detecting the amount of bound binding agent. Persons skilled in the art will appreciate that the concentration of TnTuORF in a sample can be readily calculated from the amount of TnTuORF in a sample when the sample volume is known.

In the assays, methods and kits according to the present invention, the measuring steps comprise detecting binding between a TnTuORF peptide and a binding agent that binds, selectively or specifically, to the TnTuORF peptide, and has low cross-reactivity with other markers of biological events.

Accordingly, in yet another aspect of the present invention there is provided an assay for measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from a subject with, or at risk of acquiring, a cardiac disorder other than myocardial infarction or unstable angina, comprising a binding agent that selectively binds to a TnTuORF peptide and which binding agent can be quantitatively measured upon binding to the TnTuORF peptide.

In certain embodiments, the binding agent is an antibody or an antigen-binding fragment thereof. The antibody may be a monoclonal, polyclonal, chimeric or humanized antibody or antigen-binding fragment thereof. As such, in one embodiment the assay of the present invention is an immunoassay.

The antibodies of the present invention are particularly useful in immunoassays for determining the presence and/or amount of TnTuORF in a sample. Due to variable binding affinities of different antibodies, the person skilled in the art will appreciate that a standard binding curve of measured values versus amount of TnTuORF in a sample should be established for a particular antibody to enable the amount of TnTuORF in a sample to be determined. Such a curve is used to determine the true amount of TnTuORF in a sample.

Sample materials include biological fluids but are not limited thereto. In terms of the present disclosure, usually a biological fluid is selected from whole blood, plasma or serum.

Immunoassays specific for TnTuORF peptides usually will require the production of antibodies that specifically bind to TnTuORF peptides. In one example, the antibody recognizes a TnTuORF peptide defined by MAPEGWVIVVIS (SEQ ID NO:1), MAPEGWVIVVI (SEQ ID NO: 2), MAPEGWVIVV (SEQ ID NO: 3) or MAPEGWVIV (SEQ ID NO: 4). The antibodies can be used to construct immunoassays with broad specificity, as in competitive binding assays below, or used in conjunction with other antibodies described below in sandwich type assays to produce assays specific to TnTuORF peptides. The person skilled in the art will appreciate that non-competitive assays are also possible. The latter antibodies

for sandwich immunoassays include those specific for amino acid sequences including MAPEGWVIVVIS (SEQ ID NO: 1) as well as carboxy shortened forms thereof (i.e. SEQ ID NOs: 2-4).

In another example, indicators may also be used. Indicators may be employed in ELISA and RIA assay formats.

Polyclonal and monoclonal antibodies can be used in competitive binding or sandwich type assays. In one example of this method a liquid sample is contacted with the antibody and simultaneously or sequentially contacted with a labelled TnTuORF peptide or modified peptide containing the epitope recognised by the antibody.

The label can be a radioactive component such as ^{125}I , ^{131}I , ^3H , ^{14}C or a nonradioactive component that can be measured by time resolved fluorescence, fluorescence, fluorescence polarisation, luminescence, chemiluminescence or colorimetric methods. These compounds include europium or other actinide elements, acridinium esters, fluorescein, or radioactive material such as those above, that can be directly measured by radioactive counting, measuring luminescent or fluorescent light output, light absorbance etc. The label can also be any component that can be indirectly measured such as biotin, digoxin, or enzymes such as horseradish peroxidase, alkaline phosphatase. These labels can be indirectly measured in a multitude of ways. Horseradish peroxidase for example can be incubated with substrates such as o-Phenylenediamine Dihydrochloride (OPD) and peroxide to generate a coloured product whose absorbance can be measured, or with luminol and peroxide to give chemiluminescent light which can be measured in a luminometer. Biotin or digoxin can be reacted with binding agents that bind strongly to them; e.g. avidin will bind strongly to biotin. These binding agents can in turn be covalently bound or linked to measurable labels such as horseradish peroxidase or other directly or indirectly measured labels as above. These labels and those above may be attached to the peptide or protein: during synthesis, by direct reaction with the label, or through the use of commonly available crosslinking agents such as MCS and carbodiimide, or by addition of chelating agents.

Following contact with the antibody, usually for 18 to 25 hours at 4°C ., or 1 to 240 minutes at 30°C . to 40°C ., the labelled peptide bound to the binding agent (antibody) is separated from the unbound labelled peptide. In solution phase assays, the separation may be accomplished by addition of an anti gamma globulin antibody (second-antibody) coupled to solid phase particles such as cellulose, or magnetic material. The second-antibody is raised in a different species to that used for the primary antibody and binds the primary antibody. All primary antibodies are therefore bound to the solid phase via the second antibody. This complex is removed from solution by centrifugation or magnetic attraction and the bound labelled peptide measured using the label bound to it. Other options for separating bound from free label include formation of immune complexes, which precipitate from solution, precipitation of the antibodies by polyethyleneglycol or binding free labelled

peptide to charcoal and removal from solution by centrifugation or filtration. The label in the separated bound or free phase is measured by an appropriate method such as those presented above.

Competitive binding assays can also be configured as solid phase assays that are easier to perform and are therefore preferable to those above. This type of assay uses plates with wells (commonly known as ELISA or immunoassay plates), solid beads or the surfaces of tubes. The primary antibody is either adsorbed or covalently bound to the surface of the plate, bead or tube, or is bound indirectly through a second anti gamma globulin or anti Fc region antibody adsorbed or covalently bound to the plate. Sample and labelled peptide (as above) are added to the plate either together or sequentially and incubated under conditions allowing competition for antibody binding between TnTuORF in the sample and the labelled peptide. Unbound labelled peptide can subsequently be aspirated off and the plate rinsed leaving the antibody bound labelled peptide attached to the plate. The labelled peptide can then be measured using techniques described above.

Sandwich type assays are more preferred for reasons of specificity, speed and greater measuring range. In this type of assay an excess of the primary antibody to NT-CNP is attached to the well of an ELISA plate, bead or tube via adsorption, covalent coupling, or an anti Fc or gamma globulin antibody, as described above for solid phase competition binding assays. Sample fluid or extract is contacted with the antibody attached to the solid phase. Because the antibody is in excess this binding reaction is usually rapid. A second antibody to a TnTuORF peptide is also incubated with the sample either simultaneously or sequentially with the primary antibody. This second antibody is chosen to bind to a site on NT-CNP that is different from the binding site of the primary antibody. These two antibody reactions result in a sandwich with the NT-CNP from the sample sandwiched between the two antibodies. The second antibody is usually labelled with a readily measurable compound as detailed above for competitive binding assays. Alternatively a labelled third antibody which binds specifically to the second antibody may be contacted with the sample. After washing the unbound material the bound labelled antibody can be measured by methods outlined for competitive binding assays. After washing away the unbound labelled antibody, the bound label can be quantified as outlined for competitive binding assays.

A dipstick type assay may also be used. These assays are well known in the art. They may for example, employ small particles such as gold or coloured latex particles with specific antibodies attached. The liquid sample to be measured may be added to one end of a membrane or paper strip preloaded with the particles and allowed to migrate along the strip. Binding of the antigen in the sample to the particles modifies the ability of the particles to bind to trapping sites, which contain binding agents for the particles such as antigens or antibodies, further along the strip. Accumulation of the coloured particles at these sites results in colour development are dependent on the concentration of competing

antigen in the sample. Other dipstick methods may employ antibodies covalently bound to paper or membrane strips to trap antigen in the sample. Subsequent reactions employing second antibodies coupled to enzymes such as horse radish peroxidase and incubation with substrates to produce colour, fluorescent or chemiluminescent light output will enable
 5 quantitation of antigen in the sample.

Kits

Typically, kits will be formatted for assays known in the art, and in certain embodiments for RIA or ELISA assays, as are known in the art.

10 The kits may also include one or more additional markers for the disorders noted herein. In the case of cardiac disorders, for example, the additional marker may include one or more of troponin T, troponin I, creatin kinase MB, myoglobin, ANP, BNP, BNP-SP, ANP, ANP-SP, NT-BNP, LDH, aspartate aminotransferase, H-FABP, endothelin, adrenomedullin, rennin and angiotensin II.

15 The kit may be comprised of one or more containers and may also include collection equipment, for example, bottles, bags (such as intravenous fluids bags), vials, syringes, and test tubes. At least one container will be included and will hold a product which is effective for predicting, diagnosing, or monitoring a biological event such as a cardiac disorder other than myocardial infarction or unstable angina *etc.* The product is usually a polypeptide
 20 and/or a binding agent, particularly an antibody or antigen-binding fragment of the invention, or a composition comprising any of these. In one embodiment, an instruction or label on or associated with the container indicates that the composition is used for predicting, diagnosing, or monitoring the cardiac disorder. Other components may include needles, diluents and buffers. Usefully, the kit may include at least one container
 25 comprising a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer's solution or dextrose solution.

Binding agents that selectively bind TnTuORF peptides or fragment(s) thereof are desirably included in the kit. In one embodiment, the binding agent is an antibody or antigen-binding fragment of the invention. The antibody used in the assays and kits may
 30 be monoclonal or polyclonal, for example, and may be prepared in any mammal as described above, and includes antigen binding fragments and antibodies prepared using native and fusion peptides, for example.

In one kit embodiment a TnTuORF peptide binding agent is immobilized on a solid matrix, for example, a porous strip or chip to form at least one detection site for a TnTuORF
 35 peptide or a fragment(s) thereof. The measurement or detection region of the porous strip may include a plurality of detection sites, such detection sites containing a detection reagent. The sites may be arranged in a bar, cross or dot or other arrangement. A test strip or chip may also contain sites for negative and/or positive controls. The control sites may alternatively be on a different strip or chip. The different detection sites may contain

different amounts of immobilized nucleic acids or antibodies, e.g., a higher amount in the first detection site and lower amounts in subsequent sites. Upon the addition of a test biological sample the number of sites displaying a detectable signal provides a quantitative indication of the amount of a TnTuORF peptide or a fragment(s) thereof present in the sample.

Also included in the kit may be a device for sample analysis comprising a disposable testing cartridge with appropriate components (markers, antibodies and reagents) to carry out sample testing. The device will conveniently include a testing zone and test result window. Immunochromatographic cartridges are examples of such devices. See for example US 6,399,398; US 6,235,241 and US 5,504,013.

Alternatively, the device may be an electronic device which allows input, storage and evaluation of levels of the measured marker against control levels and other marker levels. US 2006/0234315 provides examples of such devices. Also useful in the invention are CIPHERGEN's Protein Chip® which can be used to process SELDI results using CIPHERGEN's Protein Chip® software package.

Clinical Utility of TnTuORF Peptides

The clinical diagnosis of cardiac disorders including acute coronary syndromes (ACS) relies heavily on circulating diagnostic biomarkers such as cardiac troponin, including Troponin T and Troponin I. However, delays in detectable changes in circulating troponin, even with highly sensitive (hs) assays, results in clinical uncertainty in a significant number of patients presenting with a suspected cardiac disorder. Thus, identification of novel biomarkers that may provide early information in cardiac disorders is of major importance. Applicants provide here the first evidence that an upstream open reading frame (uORF) peptide is present as a distinct chemical entity in the human circulation. This uORF is derived from cardiac troponin T (TnTuORF) and is present in normal healthy individuals. The highest plasma levels of TnTuORF were observed in patients with cardiac disorders other than myocardial infarction and unstable angina, including but not limited to, for example, atrial fibrillation, heart failure, pericarditis and disorders of nerve conduction, and can therefore be used in the assays, methods and kits of the present invention to predict or diagnose a cardiac disorder in a subject.

The invention will now be illustrated with respect to the following non-limiting examples.

EXAMPLES

Example 1: Methods and Materials

5 **Chemicals**

Synthetic human TnTuORF, TnTuORF(Tyr), TnTuORF(Cys) and amino acids 1-7 of the signal peptide of vesicular integral membrane protein 36 (VIP36sp(1-7)) were synthesised by Mimotopes (Melbourne, Australia) at greater than 95% purity by mass spectrometry and high performance liquid chromatography (HPLC). All other synthetic or purified proteins were
10 purchased from Hytest (Turku, FI), Peptide Institute (Osaka, Japan) or Sigma-Aldrich (St Louis, USA).

Human TnTuORF Assay Development

Assessment of the 5' region upstream of the major open reading frame of human
15 cardiac troponin T (NCBI Accession NG_007556) identified a putative 12 amino acid peptide (full amino acid sequence MAPEGWVIVVIS; SEQ ID NO:1) encoded 1,512bp upstream of the major open reading frame (ORF) initiation site, with a Kozak score of +2 and a high likelihood of being efficiently translated (Figure 1). This sequence was not seen in fast (NCBI Accession NG_013085) or slow (NCBI Accession NG_011829) human skeletal
20 troponin T. However, examination on the NCBI BLAST search engine revealed one partial sequence, the first 7 amino acids of the signal peptide of vesicular integral membrane protein 36 (sequence MAAEGWI) as displaying homology (Fiedler *et al.* (1994) *EMBO J.* 13:1729-1740). Applicants have previously shown that signal peptides are present in the human circulation (Siriwardena *et al.* (2010) *Circulation* 122:255-264; Pemberton *et al.*
25 (2012) *Clin. Chem.* 58:757-767) and so the detection antibody was directed towards the amino terminus of TnTuORF, and VIP36sp(1-7) peptide was assessed for potential interference. Antibodies specific for the amino terminus of TnTuORF were developed according Applicants previous protocols (Siriwardena *et al.* (2010) *Circulation* 122:255-264; Pemberton *et al.* (2012) *Clin. Chem.* 58:757-767). Briefly, synthetic TnTuORF(Cys) was
30 coupled to keyhole limpet hemocyanin (KLH) and injected intradermally into four New Zealand White rabbits over 5-6 sites. Rabbits were bled 11-13 days after injection and the procedure repeated 4-6 weekly until adequate antiserum (r244) titres were obtained.

Preparation of ¹²⁵I-radiolabelled human TnTuORF(Tyr)

35 Human TnTuORF(Tyr) (2.5 µg) was iodinated using 0.5 mCi Na-¹²⁵I in the presence of 5 µg chloramine T in 5 µL of 0.5 M phosphate buffer, pH 7.3 for 15-20 s. The reaction was stopped by addition of 50 µg cysteine HCl in a further 5 µL of phosphate buffer. The resulting iodinate was loaded onto a 10 cm RP300 Brownlee HPLC column (Applied

Biosystems, San Jose, CA) and pure TnTuORF(¹²⁵I-Tyr) eluted with a gradient of 0% to 60% acetonitrile in 0.1% trifluoroacetic acid (TFA) over 15 min at a flow rate of 1 mL/min.

TnTuORF and Cardiac Marker Assays

5 For TnTuORF assay, antisera r244 was used at a final dilution of 1:15,000. All radioactive trace and antiserum were diluted in immunoassay buffer (Siriwardena *et al.* (2010) *Circulation* 122:255-264). Plasma samples and standards were diluted 1:3 in assay buffer. The assay incubate consisted of 50uL of sample or standard (0-13,000pg/mL TnTuORF peptide) mixed with 50uL of antibody at 1:5000 dilution, mixed and left to
 10 incubate for 22 hours at 4°C. 50uL of iodinated TnTuORF(Tyr) tracer (~3000cpm) was then added, tubes mixed and left to incubate for a further 22hrs at 4°C. Free and bound TnTuORF were then separated by solid-phase second antibody method (donkey anti-rabbit SacCel, Immunodiagnostic Systems, Boldon, UK). Sac-Cel (500uL) in 2% polyethylene glycol/phosphate buffer (final Sac-Cel concentration 5%) was added to each tube and left to
 15 incubate at room temperature for 30 minutes. Tubes were then centrifuged at 2800 x g for 15 minutes, the supernatant decanted and pellet counted in a Gammamaster counter (LKB, Uppsala, Sweden). Assessment of hemolysis determined that TnTuORF was not altered up to a haemoglobin concentration of up to 1.5g/L or by plasma lipid content up to 2.0g/L. NT-proBNP was determined by in-house immunoassay (Richards *et al.* (2006) *J. Am. Coll. Cardiol.* 47:52-60; Wright *et al.* (2003) *J. Am. Coll. Cardiol.* 42:1793-1800). High sensitivity TnT was determined on an Elecsys 2010 analyser (Roche Diagnostics) with a 99th percentile cut-off of 14 pg/mL. All hsTnT results were submitted to Penzberg during the worldwide reassessment of hsTnT by Roche (Apple *et al.* (2012) *Clin. Chem.* 58:1599-1600) and only 3 were reported to require adjustment. TnI was determined by a late generation
 25 assay (Abbott Architect) with a 99th percentile cut-off of 0.03 ug/L.

Human plasma sample collection

Human plasma samples were obtained from four study groups (demographic data given in Tables I and II) in accordance with ethical protocols approved by the Health and
 30 Disabilities Ethics Committee of the Ministry of Health, New Zealand. All participants gave informed consent before recruitment and all investigations conform to the principles of the Declaration of Helsinki. Plasma samples were drawn from: (i) healthy volunteers with no evidence/history of cardiovascular, endocrine or psychiatric illness (n=109), (ii) patients undergoing clinically indicated cardiac catheterisation (n=16), (iii) patients with documented
 35 ST-elevation myocardial infarction (n=4) and (iv) an ACS cohort (n=502). For this study, patients presenting to Christchurch Hospital with the primary complaint of chest pain <4 hours duration were offered recruitment into our prospective, observational study known as Signal Peptides in Acute Coronary Events (SPACE, <http://www.anzctr.org.au>, ACTRN12609000057280). Patients with the primary complaint of acute chest, epigastric,

neck, jaw or arm pain suspicious of ACS, without obvious non-cardiac origin, and lasting ≥ 20 minutes were enrolled in accordance with guideline definitions (Leupker *et al.* (2003) *Circulation* 108:2543-2549). More general/atypical symptoms (such as fatigue, nausea, vomiting, sweating and faintness) were not used as inclusion criteria. The adjudicated diagnosis of acute MI was diagnosed in accordance with the 2007 ESC/ACCF/AHA/WHF taskforce guidelines (Thygesen *et al.* (2007) *Circulation* 352:98-100) by two independent cardiologists with access to all clinical data but not TnTuORF. The biochemical component of diagnosis used an elevation of plasma cTnI ≥ 0.03 ug/L within 24 hours of admission. All relevant clinical, demographic and diagnostic parameters were collected at index admission, with follow up at 45 and 365 days.

Table I: Demographic data (mean $\pm$ SD) for patient groups (i)-(iii)

	Normal Controls (n=109)	Catheterisation (n=16)	STEMI (n=4)
Age (yrs)	43.9 $\pm$ 15.2	65.6 $\pm$ 10.6	61.3 $\pm$ 2.9
Male	40 (37%)	12 (75%)	3 (75%)
BMI (kg.m ²)	26.2 $\pm$ 4.3	29.4 $\pm$ 6.4	26.5 $\pm$ 6.6
Hypertension	27 (21.6%)	10 (63%)	2 (50%)
Diabetes	6 (5.5%)	4 (25%)	0 (0%)
Hyperlipidemia	18 (17%)	-	0 (0%)
GFR (mL/min/1.73m ²)	83.0 $\pm$ 13.5	61.9 $\pm$ 24.7	-

15

All patients had blood drawn into chilled Vacutainer tubes containing 1.8mg/mL Na³-EDTA (Becton-Dickinson). Samples were centrifuged within 2hrs of drawing and plasma stored at -80°C. For group (i), single samples were taken (after an overnight fast) from a forearm vein, immediately centrifuged to prepare plasma and stored at -80°C. Patients in group (ii) were catheterised via the left femoral artery and had blood drawn from regional vascular sites (femoral vein, renal vein, hepatic vein, inferior vena cava, jugular vein, cardiac coronary sinus and pulmonary artery). Entry and exit femoral arterial samples were taken for comparison. STEMI patients in group (iii) had forearm venous samples taken at hospital presentation at the following times after presentation: 0, 0.5hr, 1hr, 2hr, 4hr, 8hr, 12hr, 24hr, 48hr and 72hr. Patients in group (iv) had blood samples drawn at hospital presentation, and at 1, 2 and 24 hours post-presentation.

25

Table II: Demographic data (mean±SD) for patient group (iv)

	Myocardial infarction (MI)	Unstable angina pectoris (UA)	Other cardiac disorder	Non-cardiac chest pain	All patients	P-value
Patient no. (%)	114 (23)	40 (8)	26 (5)	322 (64)	502 (100)	
Gender no. (%)						
Male	77 (15)	26 (5)	16 (3)	182 (37)	302 (60)	
Female	37 (7)	14 (3)	10 (2)	139 (28)	200 (40)	
Age, yrs						
Male	66.0±13.1	64.0±8.3	65.0±14.1	59.0±13.7	62.2±13.4	
Female	78.0±12.7	66.0±7.6	72.5±6.7	68.0±13.5	68.3±12.9	<0.001
Analytes						
24 hr TnI (ug/L)						
Male	7.8±15.6	0.02±0.03	0.3±1.2	0.01±0.02	2.1±8.6	<0.001
Female	6.1±11.9	0.01±0.01	0.2±0.6	0.01±0.01	1.2±5.6	<0.001
Chol (mg.dL ⁻¹) ^ψ	181.1±60.3	175.2±45.2	173.7±31.3	186.8±59.3	183.5±57.4	
HDL (mg.dL ⁻¹) ^ψ	39.5±12.5	38.6±10.7	40.3±13.8	39.6±12.3	39.5±12.3	
LDL (mg.dL ⁻¹) ^ψ	116.3±38.8	106.7±37.7	100.7±25.6	115.5±36.9	114.2±37.1	
Trig (mg.dL ⁻¹) [§]	159.1±83.0	149.1±90.7	141.6±57.9	166.1±182.9	161.3±148.3	
Risk factor (%)						
Hypertension	78 (16)	33 (7)	20 (4)	192 (38)	323 (65)	
Diabetes	19 (4)	9 (2)	4 (1)	43 (8)	75 (15)	
BMI (kg.m ²)	28.4±5.2	27.6±4.3	28.4±5.5	28.5±6.1	28.4±5.7	
Current smoker	16 (3.5)	2 (0.5)	0 (0)	44 (9)	62 (13)	
Ever smoker	56 (11)	21 (4)	19 (4)	157 (31)	253 (50)	
History (%)						
CVD	78 (15)	36 (7)	13 (3)	199 (40)	326 (65)	
MI	36 (7)	20 (4)	10 (2)	99 (20)	165 (33)	
CABG	9 (1.5)	6 (1)	3 (0.5)	35 (7)	53 (10)	
Hyperlipidaemia	62 (12)	34 (7)	14 (3)	193 (38)	303 (60)	
Angina	48 (10)	30 (6)	17 (3)	158 (31)	253 (50)	
Heart failure	10 (2)	4 (1)	2 (0.5)	33 (6.5)	49 (10)	
ECG Findings						
LBBB	3 (1)	1 (0)	1 (0)	7 (2)	12 (4)	
ST-elevation	23 (6)	0 (0)	2 (1)	0 (0)	25 (7)	
ST-depression	10 (3)	1 (0)	3 (0.5)	2 (0.5)	16 (4)	
T-wave inversion	20 (4)	5 (1)	6 (1)	30 (7)	61 (13)	
No change	58 (9)	33 (6)	14 (3)	283 (54)	388 (72)	

^ψ = to convert mg.dL⁻¹ cholesterol to mmol/L, multiply by 0.0259

5 [§] = to convert mg.dL⁻¹ triglycerides to mmol/L, multiply by 0.0113

Purification of TnTuORF peptide from human plasma

In order to purify immunoreactive TnTuORF detected in human plasma, anti-TnTuORF IgG from r244 was purified via antigen affinity chromatography on a SulfoLink™ column (Pierce Biotechnology, IL) coupled with TnTuORF(Cys). 2 mL of r244 neat antiserum was diluted 1:1 v/v with PBS (pH 7.2) and run through the SulfoLink™ column. Bound antibody was eluted with 0.1M glycine (pH 2.5) and dialysed against 3 washes of 0.1M phosphate buffer. Purified r244 anti-TnTuORF IgG was then coupled to Protein A agarose gel (Pierce Biotechnology, IL) prepared according to the manufacturer's instructions. To obtain pure TnTuORF, 100mL of ST-elevation MI patient plasma was diluted 1:1 v/v with PBS(pH 7.2) and run through the Protein A/r244-IgG column under gravity at room temperature for 2 hours. The column was then washed with 0.1M PBS/0.5M NaCl (pH 7.2) and eluted with 0.1M glycine (pH 2.5). 1 mL fractions were collected and an aliquot diluted 1:10 v/v with immunoassay buffer and submitted to specific immunoassay to determine the quantum of purified TnTuORF. Raw glycine elution fractions were immediately stored at -80°C until assessment by HPLC.

High Performance Liquid Chromatography (HPLC)

Immunoaffinity purified TnTuORF peptide in 0.1M glycine was directly loaded onto a reverse phase (RP) HPLC column (Phenomenex, Torrance, CA) at 40°C and eluted with a gradient of 10-40% acetonitrile/0.1%TFA over 30 minutes at a flow rate of 1mL/minute. Fractions were collected at 1 minute intervals, and aliquots subjected to TnTuORF immunoassay. Immunoreactive fractions were dried under air and then subjected to size exclusion (SE) HPLC on a G2000 silica column (Toyosoda, JP) with an isocratic gradient of 60% acetonitrile/0.1%TFA at a flow rate of 0.25mL/minute. Fractions were collected at 1 minute intervals and interrogated by immunoassay as for RP-HPLC to determine approximate molecular size. RP-HPLC was calibrated with synthetic TnTuORF peptide after immunopurified TnTuORF elution. SE-HPLC runs were calibrated with cytochrome C (Mr 12,000), aprotinin (Mr 6,500), CNP22 (Mr 2,200) and angiotensin II (Mr 1,045) peptides.

Statistics

Results are presented as mean±SD. Comparison of means was carried out using paired, two tailed Students *t*-test where appropriate. Relational analysis of plasma analyte concentrations using Spearman rank order correlation testing and receiver operated curve (ROC) analysis were carried out using SPSS v17. For ROC curve generation and biomarker panel comparisons, biomarker data were analysed as standardised variables (z-scores). In all cases, the standardised variable was derived from the maximum biomarker value obtained from the t=0, 1 and 2 hour samples, ie. the maximum of the 3 values. In all analyses, a P-value <0.05 was considered significant.

Example 2: Identification of Endogenous TnTuORF in human plasma

Polyclonal antibody r244 directed towards the amino terminus of TnTuORF yielded a sensitive, specific radioimmunoassay (Figure 2), with a mean zero binding of $31 \pm 3\%$, sample detection limit of 26 ± 6 pg/mL, ED_{50} of 458 ± 105 pg/mL and a working range of 130-3900 pg/mL in which the intra-assay coefficient of variation (CV) was $<10\%$ over 25 assays. Inter-assay CVs were 14% at 1300 pg/mL and 15% at 747 pg/mL. The cross-reactivity of antisera 244 with relevant endogenous peptides, especially cardiac troponin T, troponin I and VIP36sp(1-7) and well known medications was negligible (Table III). Initial assessment confirmed that TnTuORF immunoreactivity was present in human plasma from peripheral blood collected into Na^3 -EDTA and that it diluted in parallel with the synthetic standard curve (Figure 2). Immunoreactive TnTuORF levels in normal human venous plasma (mean $\pm$ SD) were 725 ± 340 pg/mL (range 273-2260 pg/mL, 99th percentile of upper limit of normal range = 1885 pg/mL); immunoreactivity was detected in every sample. TnTuORF concentrations were significantly higher in men (825 ± 403 pg/mL vs. 666 ± 285 pg/mL, $P=0.018$) and had a significant biochemical correlation only with plasma creatinine ($r=0.201$, $P=0.036$, Figure 3). Concomitant hsTnT levels, age, blood pressures and BMI had no significant association with TnTuORF. Corresponding hsTnT levels were 6.0 ± 2.4 pg/mL (range 3.0-14.9 pg/mL) and immunoreactivity was present in 49% of samples (53/109). hsTnT levels tended to be higher in men (6.6 ± 2.4 pg/mL vs. 5.5 ± 2.3 pg/mL) and correlated significantly with age ($r=0.328$, $P=0.017$).

Table III: Cross reactivity data of r244 rabbit anti-human TnTuORF antiserum

Peptide/Drug	Cross reactivity with TnTuORF antiserum (%)
TnTuORF	100
VIP36sp(1-7)	<0.3
Cardiac Troponin T	<0.01
Cardiac Troponin I	<0.01
hFABP	<0.01
CK-MB	<0.01
proBNP(1-13)	<0.001
proBNP(1-76)	<0.001
proANP(1-30)	<0.003
ANP	<0.002
BNP	<0.003
Endothelin 1	<0.003
Angiotensin II	<0.003
Angiotensin(1-7)	<0.01
Urotensin II	<0.003
CNP22	<0.004
Clopidigrel	0
Morphine	0
Aspirin	0

All peptides are human forms.

5 Example 3: Immunoreactive TnTuORF release into the circulation

The form of TnT used for the diagnosis of MI is thought to be cardiac specific (Thygesen *et al.* (2012) *Circulation* 126:2020-2035). In line with this, Applicants anticipated that TnTuORF levels would be higher in blood draining the heart (i.e. in cardiac coronary sinus samples) than in blood supplying the heart (i.e. arterial samples). Coronary sinus plasma tended to contain higher concentrations of immunoreactive TnTuORF, compared with simultaneously drawn arterial plasma samples (978.2±118.1 pg/mL vs. 908.7±88.9 pg/mL, Mean±SD, P=0.472, Figure 4). However, elevated venous levels of TnTuORF were also observed across the hepatic vein, whereas there tended to be reduced TnTuORF levels across the femoral vein. In comparison, hsTnT levels were significantly elevated in cardiac coronary sinus plasma samples (13.1±2.7 pg/mL vs. 10.1±1.8 pg/mL, P=0.019). Renal venous levels of hsTnT were significantly lower compared with arterial levels (8.6±1.5 pg/mL vs. 10.1±1.7 pg/mL, P=0.002, Figure 4). Thus, the regional plasma profiles of TnTuORF and cTnT differed with respect to gradients of net production and clearance across organs.

Example 4: Analysis of immunoreactive species detected by RIA

Purified TnTuORF was prepared from 100 mL of plasma by immunoaffinity purification and then subjected to further identification by RP-HPLC and SE-HPLC coupled to immunoassay. Primary RP-HPLC identified two major immunoreactive peaks, the second of which eluted consistent with synthetic TnTuORF peptide (peak II, Figure 5A). On SE-HPLC, RP-HPLC derived peak II eluted at approximately 1.5K molecular weight, whereas peak I eluted at approximately 1K molecular weight (Figure 5B). Taken together, these results suggest immunoreactive TnTuORF is present in human plasma as (i) 12 amino acid intact and (ii) carboxyl terminus shortened forms, including MAPEGWVIVVI (SEQ ID NO: 2), MAPEGWVIVV (SEQ ID NO: 3) or MAPEGWVIV (SEQ ID NO: 4).

The Applicants will perform further characterisation of circulating TnTuORF peptide using tandem Ms/MS to confirm the sequence and degradation of this peptide.

Example 5: TnTuORF peptide in STEMI patients

Having established that immunoreactive TnTuORF is present in the human circulation, Applicants sought to determine the clinical utility of circulating TnTuORF as a diagnostic biomarker of acute cardiac ischemia resulting in myocardial infarction. In four patients with documented ST-elevation myocardial infarction (STEMI), whose symptom onset was less than four hours before presentation, venous concentrations of TnTuORF tended to decrease 4-5 hours after symptom onset and increased back to a plateau by 24 hours (Figure 6A). Average concentrations by 5 hours after symptom onset were almost half those seen in normal controls and did not return fully to that range by 72 hours. This profile clearly differs from that of hsTnT which rises sharply in plasma in STEMI (Figure 6B).

Example 6: TnTuORF peptide in a prospective, observational study of patients presenting with chest pain

To assess the potential of TnTuORF measurement to assist in the diagnosis of ACS, Applicants undertook a prospective, observational study of 502 patients presenting consecutively with the primary complaint of chest pain of suspected cardiac origin. Patient demographic and analyte data are given in Table II. Approximately 23% of patients had final adjudicated diagnosis of myocardial infarction (MI). Presentation TnTuORF concentrations did not have any utility to diagnose either acute MI (ROC AUC = 0.46, P=NS) or unstable angina (UA, ROC AUC =0.47, P=NS), but had good ability to diagnose patients with cardiac disorders other than ACS (AUC = 0.79, P<0.001, Figure 7) which was more accurate than NTproBNP (AUC = 0.72, P<0.001). Accordingly, maximal concentrations of TnTuORF within two hours of presentation were significantly higher in patients with non-MI, non-UA cardiac disorders, compared with all other patients groups (1159±429 pg/mL vs. 778±353 pg/mL, P<0.001). Furthermore, when TnTuORF was added to heart rate and haemoglobin (Hb) concentration, the AUC for the diagnosis of alternate

cardiac disorders improved to 0.83 ($P < 0.001$, Figure 7). hsTnT and TnI both had excellent diagnostic ability to diagnose non-ST elevation MI (NSTEMI) with ROC curves of 0.95 and 0.97, respectively (NSTEMI $n=96$, both $P < 0.001$). In comparison the product ratio of TnI x hsTnT / TnTuORF (designated here as 'TroponinPLUSTM') gave an AUC of 0.97, $P < 0.001$, Figure 8). In absolute terms, within two hours of presentation, hsTnT detected 94% of NSTEMI patients (90/96) whereas TnI detected 92% (88/96), although this improved sensitivity exhibited by hsTnT came at the cost of increased false positives (hsTnT positive non-MI patients = 68 versus TnI positive non-MI patients = 32). In comparison, TroponinPLUS detected 98% of NSTEMI patients within two hours (94/96) and generated 63 non-MI positive results. Thus, compared with hsTnT alone, the TroponinPLUS ratio increased by 4% the number of MI patients detected with two hours, and reduced the false positive rate by 7%.

With respect to prognosis, TroponinPLUS predicted mortality at 1 year (AUC = 0.74, $P < 0.001$), slightly better than hsTnT and TnI alone (AUC 0.72 and 0.71, respectively) but did not improve on either troponin T or troponin I to predict readmission with MI or CHF within one year. Addition of single inpatient 24 hour TnTuORF concentration to matched NTproBNP improved the ROC curve for 24 hour NTproBNP alone to predict readmission with acute decompensated heart failure (ADHF) with one year (0.93 vs. 0.91, Figure 9).

Discussion/Summary

Applicants results are the first demonstration of a uORF peptide as a distinct, separate entity within the circulation. It has previously been reported that a uORF peptide from GR-1A receptor is present in isolate cell cytosolic extracts (Diba *et al.* (2001) *J. Cell. Biochem.* 81:149-161), the authors did not report it being present in media used in their experiments. Applicants found no evidence on immunoassay or HPLC for TnTuORF in human plasma to be associated with hsTnT; indeed, plasma levels of TnTuORF tended to correlate negatively with hsTnT and TnI. However, Applicants cannot exclude the possibility that TnTuORF associates or binds to other plasma entities, such as autoantibodies or other binding proteins, as has been reported for both TnT and TnI (Eriksson *et al.* (2005) *N. Engl. J. Med.* 352:98-100; Savukoski *et al.* (2012) *Clin. Chem.* 58:1040-1048).

In the STEMI patient cohort interrogated (Example 1, Table I), regional plasma concentration analysis revealed the cardiac coronary sinus to contain the highest amount of hsTnT, and this observation is entirely consistent with the cardiovascular diagnostic utility of hsTnT. However, it is notable that 4/16 individuals had elevated hepatic arterio-venous hsTnT gradients, 6/16 had elevated jugular arterio-venous gradients and 11/16 had elevated femoral arterio-venous gradients. It is unlikely that this is related to assay issues as the differentials were always much larger than the assay CV. The relevance of these observations is unclear, but it may potentially contribute to the decreased diagnostic specificity observed with the hsTnT assay, especially in the context of which have been

noted as a possible source of false positive troponin T (Jaffe *et al.* (2011) *J. Am. Coll. Cardiol.* 58:1819-1824). Significantly decreased renal vein concentrations of hsTnT indicate it is likely that the kidney is a major clearance mechanism of hsTnT. With respect to TnTuORF, although Applicants observed an elevated arterio-venous gradient across the cardiac coronary sinus, this was not statistically significant.

Immunopurified TnTuORF eluted on RP- and SE-HPLC systems consistent with intact and carboxyl terminus degraded forms. TnTuORF is therefore comparable to cTnT and cTnI in terms of degradation, but whether similar enzymes or processes account for this is unknown. Importantly, in terms of immunoassay validation, cTnT and cTnI did not cross-react with the TnTuORF antibody or appear on RP- and SE-HPLC profiles. Furthermore, the closest peptide identity found, using BLAST sequence alignment tool, was VIP36sp(1-7). This peptide differs by only two amino acid from the first 7 amino acids of TnTuORF, although it was shown to have <0.3% cross-reactivity the TnTuORF peptide antibody and so minimal potential to interfere with the assay of the present invention. These data suggest that Proline at position 3 in TnTuORF plays a major part in our antibody recognition and assists with maintaining assay specificity, and full characterisation of circulating TnTuORF by tandem MS/MS will be required to confirm the sequence and degradation of this peptide.

Current evidence suggests uORFs are negatively correlated with protein production (Calvo *et al.* (2009) *Proc. Natl. Acad. Sci.* 106:7507-7512; Vogel *et al.* (2010) *Mol. Sys. Biol.* 6:400-408; Matsui *et al.* (2007) *FEBS Letts.* 581:4184-4188) but their actual functional activity has been demonstrated in only a small number of cases. For example, the production of cis-acting peptides by uORFs can reduce the initiation of translation of the downstream major ORF by stalling the ribosome at the end of the uORF (Oyama *et al.* (2004) *Genome Res.* 14:2048-2052). This evidence, coupled with Applicants observation that venous TnTuORF concentrations initially decreased in patients with documented STEMI prompted Applicants to investigate whether a potentially useful reciprocal relationship might exist between TnTuORF and hsTnT and/or TnI in patients presenting with chest pain suspicious of acute myocardial infarction. As expected, average maximal concentrations of hsTnT and TnI within two hours of presentation were significantly higher in myocardial infarction patients compared with other patient groups. In contrast, the maximal concentration of TnTuORF tended to be lower in myocardial infarction patients and was significantly lower compared with those with other cardiac disorders. Employing TnTuORF as the denominator in a ratio with cardiac Troponin T and Troponin I (TroponinPLUS™) made improvements to the diagnosis of NSTEMI and prognosis of 1 year mortality as compared with hsTnT measurement alone. Also of interest was the diagnostic performance of TnTuORF in the identification of chest pain patients presenting with cardiac disorders other than myocardial infarction, which could be improved by the addition of heart rate and Hb variables.

Although the invention has been described by way of example, it should be appreciated that variations and modifications may be made without departing from the scope of the invention as defined in the claims. Furthermore, where known equivalents exist to specific features, such equivalents are incorporated as if specifically referred in this
5 specification.

CLAIMS

1. A method of predicting a subject's risk of acquiring a cardiac disorder other than myocardial infarction or unstable angina, the method comprising:
 - 5 (i) measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from the subject; and
 - (ii) comparing the measured level of the TnTuORF peptide against a reference interval from a suitable control population,wherein an increase in the circulating level of the TnTuORF peptide compared with
10 the control population is predictive of acquiring a cardiac disorder other than myocardial infarction or unstable angina, and further wherein the measuring step comprises detecting binding between the TnTuORF peptide and a binding agent that selectively binds to the TnTuORF peptide.
- 15 2. A method of diagnosing a cardiac disorder other than myocardial infarction or unstable angina in a subject, the method comprising:
 - (i) measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from the subject; and
 - (ii) comparing the measured level of the TnTuORF peptide against a reference
20 interval from a suitable control population,wherein an increase in the circulating level of the TnTuORF peptide compared with the control population is indicative of a cardiac disorder other than myocardial infarction or unstable angina, and further wherein the measuring step comprises detecting binding between the TnTuORF peptide and a binding agent that selectively binds to the TnTuORF
25 peptide.
3. The method according to claim 1 or claim 2, comprising measuring the level of the TnTuORF peptide in a first biological sample from the subject and measuring the level of the TnTuORF peptide in a second biological sample, wherein the second biological sample is
30 taken from the same subject as the first biological sample but at a later period in time, and comparing the levels of the TnTuORF peptide in the first and second samples, wherein an increase in the circulating level of the TnTuORF peptide between the first and second samples is indicative of increased risk to acquiring a cardiac disorder other than myocardial infarction or unstable angina or is indicative of a cardiac disorder other than myocardial
35 infarction or unstable angina and/or persistence of a cardiac disorder other than myocardial infarction or unstable angina.
4. The method according to any one of claims 1 to 3, wherein the method is performed in conjunction with the analysis of one or more risk factors including heart rate,

haemoglobin concentration, blood pressure, age, sex, weight, level of physical activity, family history of events including obesity, diabetes and cardiac events, and levels of circulating Troponin T and Troponin I.

5 5. The method according to claim 4, wherein the risk factors include heart rate and haemoglobin concentration.

6. The method according to any one of claims 1 to 5, further comprising (iii) administering a treatment regimen to the subject where the subject is found to have an
10 increase in a circulating level of the TnTuORF peptide compared with the circulating level of the TnTuORF peptide in the control population.

7. A method for monitoring the responsiveness of a subject to treatment with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina, the
15 method comprising:

 (i) measuring the level of TnTuORF in a first biological sample from the subject;
 (ii) measuring the level of TnTuORF in a second biological sample from the subject,
 wherein the second biological sample is taken from the same subject; and
 (iii) comparing the measured levels of TnTuORF in the first and second samples,
20 wherein an increase in the level of TnTuORF between the first and second samples is indicative of a poor response to treatment with a with a drug or therapy for a cardiac disorder other than myocardial infarction or unstable angina and wherein a decrease in the level of TnTuORF between the first and second samples is indicative of a positive response to a to treatment with a with a drug or therapy for a cardiac disorder other than myocardial
25 infarction or unstable angina.

8. The method according to any one of claims 1 to 7, wherein the control population is sex and age-matched subjects for which the cardiac disorder is known.

30 9. The method according to any one of claims 1 to 8, wherein the reference interval is the mean circulating TnTuORF peptide concentration from the control population.

10. The method according to any one of claims 1 to 9, wherein the cardiac disorder is selected from atrial fibrillation, heart failure, pericarditis, disorders of nerve conduction,
35 vasovagalsyncope or combinations of any of these.

11. The method according to any one of claims 1 to 10, wherein the biological sample is body fluid or a heart tissue sample.

12. The method according to claim 11, wherein the body fluid is selected from blood including venous blood and arterial blood, plasma, serum and interstitial fluid.

13. The method according to any one of claims 1 to 12 wherein the binding agent is an antibody or antigen binding fragment thereof.

14. The method according to claim 13 wherein the antibody is selected from a polyclonal, monoclonal, chimeric or humanised antibody or antigen binding fragment thereof.

15. The method according to claim 14 wherein the antibody is a monoclonal antibody of antigen binding fragment thereof.

16. The method according to any one of claims 13 to 15 wherein the binding agent or antibody is immobilised to a solid phase.

17. The method according to any one of claims 1 to 16 wherein the Troponin T upstream open reading frame (TnTuORF) peptide consists in the amino acid sequence set forth in any one of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4.

18. An assay for measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from a subject with, or at risk of acquiring, a cardiac disorder other than myocardial infarction or unstable angina, the assay comprising a binding agent that selectively binds to a TnTuORF peptide and which can be quantitatively measured upon binding to the TnTuORF peptide in a biological sample from the subject.

19. An assay according to claim 18, wherein the assay comprises:

- (i) measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from the subject; and
- (i) comparing the measured level of the TnTuORF peptide against a reference interval from a suitable control population,

wherein an increase in the circulating level of the TnTuORF peptide compared with the control population is predictive of acquiring a cardiac disorder other than myocardial infarction or unstable angina, or is diagnostic of a subject with a cardiac disorder other than myocardial infarction or unstable angina, and further wherein the measuring step comprises detecting binding between the TnTuORF peptide and a binding agent that selectively binds to the TnTuORF peptide.

20. The assay according to claim 18 or claim 19 which is an immunoassay, an enzyme immunoassay, a radioimmunoassay or a chemiluminescence assay.

21. The assay according to any one of claims 18 to 20 wherein the binding agent is an antibody or antigen binding fragment thereof.

22. A kit for measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from a subject with, or at risk of acquiring, a cardiac disorder other than myocardial infarction or unstable angina, comprising a binding agent that selectively binds to a TnTuORF peptide and which can be quantitatively measured upon binding to TnTuORF.

23. The kit according to claim 22 wherein the binding agent is an antibody or antigen binding fragment thereof.

24. The kit according to claim 21 or claim 22, further comprising instructions for how to measure the level of TnTuORF peptide in the sample.

25. A Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds TnTuORF peptide for use in predicting a subject's risk of acquiring a cardiac disorder other than myocardial infarction or unstable angina.

26. A Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds TnTuORF peptide for use in diagnosing a cardiac disorder other than myocardial infarction or unstable angina in a subject.

27. Use of a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a TnTuORF peptide in the manufacture of a medicament for predicting a subject's risk for acquiring a cardiac disorder other than myocardial infarction or unstable angina.

28. Use of a Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a TnTuORF peptide in the manufacture of a medicament for diagnosing a cardiac disorder other than myocardial infarction or unstable angina in a subject.

29. An isolated Troponin T upstream open reading frame (TnTuORF) peptide.

30. The isolated TnTuORF peptide according to claim 26 consisting the amino acid sequence set forth in any of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4.
31. An assay for improving the sensitivity and false positive performance of cardiac troponin in predicting a subject's risk of myocardial infarction, the assay comprising a binding agent that selectively binds to a Troponin T upstream open reading frame (TnTuORF) peptide and which binding agent can be quantatively measured upon binding to the TnTuORF peptide in a biological sample from the subject.
32. An assay for improving the sensitivity and false positive performance of cardiac troponin in diagnosing myocardial infarction in a subject, the assay comprising a binding agent that selectively binds to a Troponin T upstream open reading frame (TnTuORF) peptide and which binding agent can be quantatively measured upon binding to the TnTuORF peptide in a biological sample from the subject
33. The assay according to claim 31 or claim 32, wherein the cardiac troponin comprises Troponin T and Troponin I.
34. The assay according to any one of claims 31 to 33, wherein the cardiac troponin is represented by high sensitivity Troponin T x Troponin I.
35. The assay according to any one of claims 31 to 34, wherein the sensitivity and false positive performance of cardiac troponin is improved by taking the product ratio of cardiac troponin to TnTuORF peptide.
36. The assay according to claim 35, wherein product ratio is represented by high sensitivity troponin T x Troponin I / TnTuORF peptide.
37. An assay for predicting mortality in a subject following a cardiac event, the assay comprising a binding agent that selectively binds to a Troponin T upstream open reading frame (TnTuORF) peptide and which binding agent can be quantatively measured upon binding to the TnTuORF peptide in a biological sample from the subject.
38. An assay for improving the sensitivity and false positive performance of N-terminal brain natriuretic peptide (NT-proBNP) in predicting a subject's risk of acquiring acute decompensated heart failure following a cardiac event, the assay comprising a binding agent that selectively binds to a Troponin T upstream open reading frame (TnTuORF) peptide and which binding agent can be quantatively measured upon binding to the TnTuORF peptide in a biological sample from the subject.

39. A kit for measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from a subject for use in improving the sensitivity and false positive performance of cardiac troponin in predicting or diagnosing myocardial infarction in the subject, the kit comprising a binding agent that selectively binds to a TnTuORF peptide and which binding agent can be quantatively measured upon binding to TnTuORF.

40. a kit for measuring the level of a Troponin T upstream open reading frame (TnTuORF) peptide in a biological sample from a subject for use in improving the sensitivity and false positive performance of N-terminal brain natriuretic peptide (NT-proBNP) in predicting the subject's risk of acquiring acute decompensated heart failure following a cardiac event, the kit comprising a binding agent that selectively binds to a TnTuORF peptide and which binding agent can be quantatively measured upon binding to TnTuORF.

41. A Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a TnTuORF peptide in a biological sample from a subject for use in improving the sensitivity and false positive performance of cardiac troponin in predicting or diagnosing myocardial infarction in the subject.

42. A Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a TnTuORF peptide in a biological sample from a subject for use in predicting mortality of the subject following a cardiac event.

43. A Troponin T upstream open reading frame (TnTuORF) peptide binding agent that selectively binds to a TnTuORF peptide in a biological sample from a subject for use in improving the sensitivity and false positive performance of N-terminal brain natriuretic peptide (NT-proBNP) in predicting the subject's risk of acquiring acute decompensated heart failure following a cardiac event.

1/9



FIGURE 1

FIGURE 2



3/9


FIGURE 3

FIGURE 4





FIGURE 5



6/9



FIGURE 6

FIGURE 7



8/9



FIGURE 8

FIGURE 9



INTERNATIONAL SEARCH REPORT

International application No.
PCT/NZ2014/000234

A. CLASSIFICATION OF SUBJECT MATTER

G01N 33/68 (2006.01) G01N 33/53 (2006.01) C07K 7/08 (2006.01) C07K 7/06 (2006.01) C07K 16/18 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPODOC, WPI, MEDLINE, BIOSIS, HCAPLUS, EMBASE: troponin, cTnT, UORF, upstream open reading frame, TnTuORF, UTR, peptide and like terms

GenomeQuest: SEQ ID NOs: 1-4

Espacenet: inventor/applicant search, troponin, myocardial, cardiomyopathy, fibrillation, pericarditis, vasovagal, cardiac, heart

Google Scholar: inventor search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	



Further documents are listed in the continuation of Box C



See patent family annex

* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 23 January 2015	Date of mailing of the international search report 23 January 2015
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA Email address: pct@ipaustalia.gov.au	Authorised officer Jonathan Konrad AUSTRALIAN PATENT OFFICE (ISO 9001 Quality Certified Service) Telephone No. +61 2 6283 2601

INTERNATIONAL SEARCH REPORT		International application No.
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		PCT/NZ2014/000234
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Aldous, S. et al., 'High-sensitivity troponin T for early rule-out of myocardial infarction in recent onset chest pain', Emergency Medicine Journal, 2012, Vol. 29, pages 805-810 See the whole document, particularly the title and abstract	
A	US 6,376,206 B1 (Katus et al.) 23 April 2002 See the whole document, particularly Example 8 and the title, abstract and claims	
A	EP 2261669 A1 (Alere San Diego, Inc.) 15 December 2010 See the whole document, particularly the abstract and claims	
A	US 2012/0129198 A1 (Buechler et al.) 24 May 2012 See the whole document, particularly [0008]-[0012], [0034], [0048]-[0049], [0064] and the examples	
A	WO 2008/030122 A1 (UNIVERSITY OF OTAGO) 13 March 2008 See the whole document, particularly page 6 second paragraph and page 44 last paragraph	
A	WO 2013/017690 A2 (ROCHE DIAGNOSTICS GMBH et al.) 07 February 2013 See the whole document, particularly page 3 and the abstract and claims	
P,X	Pemberton, C. J. et al., 'A novel human cardiac troponin T upstream open reading frame peptide assists in the diagnosis and prognosis of NSTEMI patients', Circulation, 26 November 2013, Vol. 138, No. 22, Supplement, Abstract 9552 See whole document	1-43
P,X	Pemberton, C. J. et al., 'A novel troponin T peptide in acute breathless patients presenting to ED', European Heart Journal, published online 2 September 2014, Vol. 35, Supplement 1, page 1180 See whole document	1-43

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing filed or furnished:
- a. (means)
- ☐ on paper
- ☐ in electronic form
- b. (time)
- ☐ in the international application as filed
- ☐ together with the international application in electronic form
- ☐ subsequently to this Authority for the purposes of search
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:
- SEQ ID NOs: 1-4 in the description were used for searching purposes.

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/NZ2014/000234	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
US 6,376,206 B1	23 April 2002	DE 3922873 A1	31 Oct 1990
		EP 0394819 A2	31 Oct 1990
		EP 0394819 B1	18 Jan 1995
		HK 1002814 A1	18 Sep 1998
		JP H037597 A	14 Jan 1991
		JP 2564686 B2	18 Dec 1996
		JP H07198718 A	01 Aug 1995
		JP 2818116 B2	30 Oct 1998
		US 6333397 B1	25 Dec 2001
EP 2261669 A1	15 December 2010	AU 2002252636 B2	08 Mar 2007
		AU 2002305394 A1	18 Nov 2002
		AU 2003300407 A1	22 Jul 2004
		AU 2003302340 A1	22 Jul 2004
		AU 2003302340 B2	21 Aug 2008
		AU 2004232990 A1	04 Nov 2004
		AU 2007201180 A1	19 Apr 2007
		AU 2007201180 B2	25 Nov 2010
		CA 2412648 A1	24 Oct 2002
		CA 2414073 A1	14 Nov 2002
		CA 2457775 A1	27 Feb 2003
		CA 2511482 A1	15 Jul 2004
		CA 2511501 A1	15 Jul 2004
		CA 2522670 A1	04 Nov 2004
		CA 2522709 A1	04 Nov 2004
		CA 2535971 A1	03 Mar 2005
		CA 2579802 A1	16 Mar 2006
		CA 2692217 A1	15 Jul 2004
		CN 1751128 A	22 Mar 2006
		EP 1311701 A1	21 May 2003
		EP 1311701 B1	23 Jul 2008
		EP 1322957 A2	02 Jul 2003
		EP 1322957 B1	12 Aug 2009
		EP 1419388 A1	19 May 2004
		EP 1419388 B1	07 Oct 2009

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/NZ2014/000234	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		EP 1587955 A2	26 Oct 2005
		EP 1588159 A2	26 Oct 2005
		EP 1616181 A2	18 Jan 2006
		EP 1616181 B1	12 Aug 2009
		EP 1620726 A2	01 Feb 2006
		EP 1656555 A1	17 May 2006
		EP 1656555 B1	21 Mar 2012
		EP 1666881 A2	07 Jun 2006
		EP 1666881 B1	17 Feb 2010
		EP 1786931 A2	23 May 2007
		EP 1786931 B1	27 Jan 2010
		EP 1867734 A1	19 Dec 2007
		EP 1983058 A1	22 Oct 2008
		EP 1983058 B1	18 Dec 2013
		JP 2004519688 A	02 Jul 2004
		JP 3749225 B2	22 Feb 2006
		JP 2004520598 A	08 Jul 2004
		JP 3806694 B2	09 Aug 2006
		JP 2005049351 A	24 Feb 2005
		JP 4119408 B2	16 Jul 2008
		JP 2006234823 A	07 Sep 2006
		JP 4235652 B2	11 Mar 2009
		JP 2008512685 A	24 Apr 2008
		JP 4733704 B2	27 Jul 2011
		JP 2011257407 A	22 Dec 2011
		JP 5460649 B2	02 Apr 2014
		JP 2005121664 A	12 May 2005
		JP 2005522669 A	28 Jul 2005
		JP 2006523849 A	19 Oct 2006
		JP 2006526140 A	16 Nov 2006
		JP 2006527190 A	30 Nov 2006
		JP 2007502991 A	15 Feb 2007
		JP 2009103721 A	14 May 2009
		NZ 523210 A	27 Apr 2007
		NZ 532625 A	30 May 2008
		US 2005064511 A1	24 Mar 2005

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/NZ2014/000234	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		US 7341838 B2	11 Mar 2008
		US 2006063204 A1	23 Mar 2006
		US 7358055 B2	15 Apr 2008
		US 2003109420 A1	12 Jun 2003
		US 7361473 B2	22 Apr 2008
		US 2003119064 A1	26 Jun 2003
		US 7427490 B2	23 Sep 2008
		US 2005148024 A1	07 Jul 2005
		US 7524635 B2	28 Apr 2009
		US 2005255484 A1	17 Nov 2005
		US 7608406 B2	27 Oct 2009
		US 2003022235 A1	30 Jan 2003
		US 7632647 B2	15 Dec 2009
		US 2004121343 A1	24 Jun 2004
		US 7713705 B2	11 May 2010
		US 2003199000 A1	23 Oct 2003
		US 2003219734 A1	27 Nov 2003
		US 2004121350 A1	24 Jun 2004
		US 2004126767 A1	01 Jul 2004
		US 2004171064 A1	02 Sep 2004
		US 2004176914 A1	09 Sep 2004
		US 2004203083 A1	14 Oct 2004
		US 2004209307 A1	21 Oct 2004
		US 2004219509 A1	04 Nov 2004
		US 2004253637 A1	16 Dec 2004
		US 2006177870 A1	10 Aug 2006
		US 2008008696 A1	10 Jan 2008
		US 2008045444 A1	21 Feb 2008
		US 2008160540 A1	03 Jul 2008
		US 2009275512 A1	05 Nov 2009
		US 2011065210 A1	17 Mar 2011
		WO 02083913 A1	24 Oct 2002
		WO 02089657 A2	14 Nov 2002
		WO 03016910 A1	27 Feb 2003
		WO 2004058055 A2	15 Jul 2004
		WO 2004059293 A2	15 Jul 2004

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/NZ2014/000234

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report**Patent Family Member/s****Publication Number****Publication Date****Publication Number****Publication Date**

WO 2004094459 A2

04 Nov 2004

WO 2004094460 A2

04 Nov 2004

WO 2004097368 A2

11 Nov 2004

WO 2005019819 A1

03 Mar 2005

WO 2005071421 A1

04 Aug 2005

WO 2006029369 A2

16 Mar 2006

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/NZ2014/000234	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
US 2012/0129198 A1	24 May 2012	AU 1929199 A	12 Jul 1999
		AU 5665696 A	07 Nov 1996
		AU 5799898 A	15 Jul 1998
		CA 2218491 A1	24 Oct 1996
		CA 2275294 A1	25 Jun 1998
		CA 2315186 A1	01 Jul 1999
		EP 0821794 A1	04 Feb 1998
		EP 0821794 B1	03 Nov 2004
		EP 0821794 B2	11 Aug 2010
		EP 0935140 A2	11 Aug 1999
		EP 0935140 B1	02 Oct 2013
		EP 0946879 A1	06 Oct 1999
		EP 0946879 B1	08 Jun 2005
		EP 1042675 A1	11 Oct 2000
		EP 1042675 B1	31 Jan 2007
		EP 1591789 A2	02 Nov 2005
		EP 1591789 B1	03 Mar 2010
		EP 2172776 A1	07 Apr 2010
		JP H11505605 A	21 May 1999
		JP 3065667 B2	17 Jul 2000
		US 5795725 A	18 Aug 1998
		US 6156521 A	05 Dec 2000
		US 6174686 B1	16 Jan 2001
		US 6579687 B1	17 Jun 2003
		US 6627404 B1	30 Sep 2003
		US 6939678 B1	06 Sep 2005
		US 6991907 B1	31 Jan 2006
		US 2005164317 A1	28 Jul 2005
		US 7604946 B2	20 Oct 2009
		US 2007196880 A1	23 Aug 2007
		US 7723059 B2	25 May 2010
		US 2011014629 A1	20 Jan 2011
		US 8084224 B2	27 Dec 2011
		US 2011143455 A1	16 Jun 2011
		US 8114612 B2	14 Feb 2012

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/NZ2014/000234	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
WO 2008/030122 A1	13 March 2008	US 2003211544 A1	13 Nov 2003
		US 2010167307 A1	01 Jul 2010
		WO 9633415 A1	24 Oct 1996
		WO 9827435 A1	25 Jun 1998
		WO 9932888 A1	01 Jul 1999
		AU 2007293777 A1	13 Mar 2008
		AU 2007293777 B2	20 Mar 2014
		CA 2662629 A1	13 Mar 2008
		CN 101611318 A	23 Dec 2009
		EP 2089722 A1	19 Aug 2009
WO 2013/017690 A2	07 February 2013	JP 2010506145 A	25 Feb 2010
		NZ 576061 A	22 Feb 2013
		US 2009239246 A1	24 Sep 2009
		US 8298772 B2	30 Oct 2012
		US 2013183683 A1	18 Jul 2013
		US 2013316378 A1	28 Nov 2013
		EP 2554995 A1	06 Feb 2013
		US 2013035603 A1	07 Feb 2013
End of Annex			
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			

专利名称(译)	心脏疾病的生物标志物		
公开(公告)号	EP3069146A4	公开(公告)日	2017-04-05
申请号	EP2014861343	申请日	2014-11-14
[标]申请(专利权)人(译)	奥塔哥创新有限公司		
申请(专利权)人(译)	奥塔哥创业有限公司		
当前申请(专利权)人(译)	奥塔哥创业有限公司		
[标]发明人	LEE JACQUELINE AMANDA PEMBERTON CHRISTOPHER JOSEPH		
发明人	LEE, JACQUELINE AMANDA PEMBERTON, CHRISTOPHER JOSEPH		
IPC分类号	G01N33/68 G01N33/53 C07K7/08 C07K7/06 C07K16/18 C07K14/47		
CPC分类号	G01N33/6893 C07K14/4716 C07K16/18 C07K2317/33 C07K2317/34 G01N33/6887 G01N2333/4712 G01N2800/32 G01N2800/50 G01N2800/52		
优先权	61/904957 2013-11-15 US		
其他公开文献	EP3069146A1		
外部链接	Espacenet		

摘要(译)

本发明一般涉及用于心脏病的预后和/或诊断的测定，方法和试剂盒。本发明还提供例如结合剂用于新型循环心肌钙蛋白T上游开放阅读框 (TnTuORF) 肽生物标记物，用于预测或诊断除心肌梗塞或不稳定性心绞痛之外的心脏病。此外，本发明的结合剂可用于增强心肌钙蛋白在心肌梗塞的预后和诊断中的敏感性和假阳性。